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ABSTRACT
Objective To investigate the role of salivary small non- 
coding RNAs (sncRNAs) in the diagnosis of sport- related 
concussion.
Methods Saliva was obtained from male professional 
players in the top two tiers of England’s elite rugby 
union competition across two seasons (2017–2019). 
Samples were collected preseason from 1028 players, 
and during standardised head injury assessments 
(HIAs) at three time points (in- game, post- game, and 
36–48 hours post- game) from 156 of these. Samples 
were also collected from controls (102 uninjured players 
and 66 players sustaining a musculoskeletal injury). 
Diagnostic sncRNAs were identified with next generation 
sequencing and validated using quantitative PCR in 702 
samples. A predictive logistic regression model was built 
on 2017–2018 data (training dataset) and prospectively 
validated the following season (test dataset).
Results The HIA process confirmed concussion in 
106 players (HIA+) and excluded this in 50 (HIA−). 
32 sncRNAs were significantly differentially expressed 
across these two groups, with let- 7f- 5p showing the 
highest area under the curve (AUC) at 36–48 hours. 
Additionally, a combined panel of 14 sncRNAs (let- 7a- 
5p, miR-143- 3p, miR- 103a- 3p, miR- 34b- 3p, RNU6-7, 
RNU6-45, Snora57, snoU13.120, tRNA18Arg- CCT, 
U6-168, U6-428, U6-1249, Uco22cjg1,YRNA_255) 
could differentiate concussed subjects from all other 
groups, including players who were HIA− and controls, 
immediately after the game (AUC 0.91, 95% CI 0.81 to 
1) and 36–48 hours later (AUC 0.94, 95% CI 0.86 to 1). 
When prospectively tested, the panel confirmed high 
predictive accuracy (AUC 0.96, 95% CI 0.92 to 1 post- 
game and AUC 0.93, 95% CI 0.86 to 1 at 36–48 hours).
Conclusions SCRUM, a large prospective observational 
study of non- invasive concussion biomarkers, has 
identified unique signatures of concussion in saliva of 
male athletes diagnosed with concussion.
INTRODUCTION
Sport- related concussion is defined as ‘a traumatic 
brain injury induced by biomechanical forces that 
typically results in the rapid onset of short- lived 
impairment of neurological function that resolves 
spontaneously›.1 A high percentage of cases may 
go misdiagnosed or unidentified and concerns 
have emerged about the long- term brain health of 
athletes exposed to repeated concussions.
The extremely poor objective diagnostic tests 
after an index event has the potential to expose 
individuals to the risk of further single or multiple 
concussive events before the initial concussion has 
resolved. Conventional neuroimaging (CT and MRI 
scanning) is normal by definition, and the diagnosis 
currently relies on a clinician’s interpretation of the 
observed signs, symptoms reported and cognitive/
neuropsychometric and/or physical evaluations (eg, 
balance or oculo- vestibular assessments).2 3 The 
assessments are not specific for concussion and 
require subject honesty and cooperation, operator 
training and prescriptive test conditions. The short- 
term consequences of a missed diagnosis range from 
a prolonged recovery period, often with protracted 
and pervasive symptoms, to a heightened risk of 
further injuries, including rarely, catastrophic brain 
swelling (second impact syndrome).4 5
In recent years, there has been focus on the 
development and validation of objective diag-
nostic tools for concussion, both within traditional 
clinical settings and pitch side at sporting events. 
Several blood biomarkers have been intensively 
studied, including S100β, glial fibrillar acidic 
protein (GFAP), ubiquitin carboxy- terminal hydro-
lase L1 (UCH- L1), neuron- specific enolase (NSE), 
Tau, neurofilament light protein (NFL) and beta- 
amyloid protein.6–10
A blood assay using GFAP and UCH- L1 has 
Food and Drug Administration approval to eval-
uate the requirement for a CT scan and rule out 
haemorrhagic pathology in traumatic brain injury 
(TBI). However, diagnosis of concussion expands 
beyond the exclusion of pathology visible on CT 
imaging, as the majority of injuries will not result in 
structural abnormalities identifiable with standard 
imaging methods.11–13
Recently, rapid advances in high- throughput 
technologies, such as next generation sequencing 
(NGS), have allowed investigation of new classes 
of molecules, such as RNA species, as potential 
biomarkers. Among these, microRNAs (miRNAs, 
miRs), which belong to the small non- coding RNAs 
(sncRNAs) (20–200 nucleotides in length), are the 
most studied, with evidence of a miRNA signature 
that varies according to TBI severity in blood, cere-
brospinal fluid (CSF) and saliva .14–24 However, 
other classes of sncRNAs such as small nuclear RNA 
(snRNA), small nucleolar RNA (snoRNA), transfer 
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RNA (tRNA), YRNA and piwiRNA (piRNA) have emerged as 
new candidate biomarkers in several pathologies. The role of 
the majority of these molecules is not fully understood, but it 
is evident that 90% of our genome encoding for untranslated 
RNA has functional activity in normal biology and in patholog-
ical conditions.25–27
In professional male rugby union in England, clinicians’ eval-
uations of athletes who have sustained a head injury with the 
potential to result in concussion are supported by a standardised 
head injury assessment (HIA) protocol,28 providing an excellent 
setting in which to examine biomarkers of concussion and clin-
ical outcomes.
We assessed sncRNAs as potential salivary biomarkers of 
sport- related concussion in professional male rugby players, 
with the following objectives
 ► Biomarkers identification: To discover whether any sncRNAs 
are differentially expressed in players with a clinical diag-
nosis of concussion compared with other groups.
 ► Longitudinal analysis: To evaluate the time course of the 
sncRNA expression response in players with a clinical diag-
nosis of concussion.
 ► Biomarkers validation and predictive model: To determine 
whether a combination of sncRNAs can predict the outcome 




The Study of Concussion in Rugby Union through MicroRNAs 
(SCRUM) is a prospective, observational cohort study in which 
cases and controls are compared, and is part of the REpetitive 
COncussion in Sport (RECOS) research programme.29 The study 
was carried out in the highest two tiers of senior male profes-
sional domestic rugby union in England in the 2017–2018 and 
2018–2019 seasons. The study was authorised by the University 
Figure 1 Study profile. Participants were divided into concussion confirmed (HIA+) or ruled out (HIA−) after their head injury assessment (HIA), 
or controls, represented by players who played in the same game but were uninjured or had had a musculoskeletal injury. Twenty- three HIAs were 
excluded from the analysis owing to insufficient information to confirm the diagnosis from the HIA records and/or video footage after independent 
review. Twenty- four further HIAs were ineligible for inclusion, as the samples failed quality control checks.
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of Birmingham research ethics committee and by the East of 
England NHS ethics committee (ref. 11- 0429AP28). All partic-
ipants gave written informed consent in accordance with the 
Declaration of Helsinki. The study was preregistered with the 
International Standard Randomised Controlled Trials Number 
in February 2018 (ISRCTN16974791), it followed the Strength-
ening the Reporting of Observational Studies in Epidemiology 
(STROBE) reporting guideline, and the methodology, including 
the analysis plan, was published in 2018.30
Participants
A total of 1028 participants were recruited to the study 
(figure 1). In season 1 (2017–2018), players from 11 (out of 
12) England’s Premiership (highest league) and 11 (out of 12) 
Championship (second league) clubs participated. One Cham-
pionship club subsequently withdrew after the baseline sample 
collection owing to lack of resources to support the study. In 
season 2 (2018–2019) players from 11 (out of 12) Premiership 
clubs took part. Championship clubs were involved in a separate 
evaluation of concussion prevention.31 During and after games, 
following evaluation using the HIA protocol, participants for 
whom concussion was confirmed were categorised as HIA+ and 
participants for whom concussion was ruled out were catego-
rised as HIA−. Uninjured players from the same game, matched 
for number of minutes played (uninjured controls), and players 
removed owing to musculoskeletal injuries (MSK controls) 
provided control samples. Participant characteristics are shown 
in table 1.
Study design
Saliva samples were collected preseason (baseline, B). During 
games, if a player required an HIA, saliva was collected per 
protocol. World Rugby (the International Federation) sanc-
tioned an extension of the time permitted for an in- game HIA 
assessment from 10 min to 13 min to allow for saliva collec-
tion. In- game samples (T1), were followed by post- game (T2) 
and 36–48 hours post- game (T3) samples. Uninjured and MSK 
controls provided samples at T2 and T3 time points. In season 
2, samples were not collected at T1 because sufficient data at this 
time point had been collected in season 1, and because T2 is the 
pre- established time point of the study.30
HIA protocol
The HIA protocol has been described in detail,28 and is a 
three time point multimodal assessment process performed by 
trained team physicians that incorporates: (i) HIA1: in- game, 
immediate removal of players showing clear signs of concus-
sion, or, where a meaningful head impact has occurred without 
clear signs of concussion, a temporary substitution to allow 
the team physician to perform an off- field medical assessment 
aligned with the Sports Concussion Assessment Tool version 
5 (SCAT5),32 (ii) HIA2: post- game medical assessment within 
3 hours of a head impact supported by the SCAT5, and (iii) 
HIA3: medical assessment 36–48 hours after a head impact to 
monitor clinical progress and to confirm or refute the diag-
nosis of concussion, supported by the SCAT5. If there is no 
suspicion of concussion following the HIA1, the player can 
return to play, but they still complete HIA2 and HIA3 assess-
ments. All medical staff involved in the delivery of the HIA 
protocol undertake annual mandatory training and weekly 
formal review (supported by video); governance and disci-
plinary processes are in place to monitor compliance. In order 
to ensure a consistent diagnostic standard for the study, at 
the end of each season the full HIA protocol documentation 
for each player assessed for concussion and (where available) 
the video footage of the inciting head injury were reviewed 
independently against the HIA protocol by two experienced 
sports medicine doctors. They were blinded to any laboratory 
results and adjudicated each incident as HIA+ or HIA− or 
recommended exclusion of the incident due to insufficient or 
conflicting evidence. This resulted in the exclusion of 47 HIAs 
(figure 1).
Saliva collection
Saliva (2 mL) was collected in by passive drool in Oragene- RNA 
RE-100 saliva self- collection kits (DNA Genotek) containing 
an RNA stabilising solution preserving the samples for up to 
8 weeks. In the laboratory, samples were processed according 
to the manufacturer’s protocol for storage. During the second 
season, the RE-100 kits were discontinued and replaced with 




In order to discover any sncRNAs that might be implicated 
in the response to concussion in an unbiased way, NGS was 
performed using 15 baseline samples, 15 HIA+ post- game 
(T2) samples and 20 control T2 samples (10 MSK and 10 unin-
jured controls) from season 1. The false discovery rate was 
minimised using the Benjamini- Hochberg procedure, which 
allowed the strongest candidates, in terms of fold change and 
significance, to be taken forward for quantitative PCR (qPCR) 
analysis. No fold- change cut- off point was selected. Details 
of the full NGS procedure are provided in the online supple-
mental material.
Table 1 Participants’ demographics
Characteristics HIA+ group (n=106) HIA− group (n=50) Uninjured group (n=102) MSK group (n=66)
Test statistic
F or Χ2 P value
Age, mean (SD), years 27.1 (4.0) 27.5 (3.4) 26.4 (4.1) 25.9 (3.6) 2.25 0.08
Height, mean (SD), cm 186 (7) 188 (7) 186 (8) 187 (6) 0.43 0.73
Weight, mean (SD), kg 104.1 (11.9) 106.5 (12.7) 105.3 (12.7) 106.3 (12.2) 0.57 0.64
Minutes Played, mean (SD), min 37.8 (23.1) 54.6 (18.6) 52.8 (27.3) 55.6 (23.1) 10.38 *0.00
Ethnicity, No (%)
  White (British/Irish/other) 72 (82%) 35 (76%) 74 (84%) 48 (84%)
  Black or black British 2 (2%) 2 (4%) 3 (3%) 3 (5%)
  Other ethnic group 14 (16%) 9 (20%) 14 (15%) 6 (11%)
Age, height, weight and ethnicity (where disclosed) of participants.
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sncRNA qPCR data analysis in season 1
To measure accurately the candidate biomarkers identified by 
the NGS, qPCR analysis was carried out on all available samples 
from season 1 at QIAGEN Genomic Services, (Germany). This 
included 393 in- match and post- match samples and 176 corre-
sponding baseline samples. qPCR normalisation was performed 
based on the average of hsa- miR- 29c- 3p and hsa- let- 7b- 5p, 
the two most stable miRs identified across all samples by 
Normofinder software. The full qPCR procedure is described in 
the supplementary material.
Normalised ΔCq values were checked for normal distribution 
and then two- tailed independent- samples t- tests were performed 
to compare means of pair groups (HIA+ vs HIA− at T1, T2 
and T3; HIA+ vs uninjured at T2 and T3; HIA+ vs MSK at 
T2 and T3; univariate analysis). In HIA+ samples, two- tailed 
paired- samples t- tests were performed to compare the means of 
baseline and concussion levels of the same subjects. Accuracy is 
reported as area under the curve (AUC) on a receiver operating 
characteristics plot.
Time course of concussion biomarkers
Analysis of variance was performed in HIA+ and HIA− groups 
over time (baseline, T1, T2 and T3). Comparisons across 
multiple time points were evaluated using post- hoc Tukey’s 
honestly significant difference test. A corrected p<0.05 was 
considered significant.
Biomarker validation and predictive model 
sncRNA qPCR data analysis in season 2
In season 2, all significantly expressed biomarkers identified 
in season 1 across the different comparisons (HIA+ vs HIA−; 
HIA+ vs uninjured; HIA+ vs MSK) were analysed on a total 137 
samples by qPCR as described in the supplementary material. 
t- Tests were performed for each group comparisons.
Development and testing of the multivariate predictive model
The concussion classification accuracy of the sncRNAs selected 
in season 1 (HIA+ vs HIA−, uninjured and MSK combined at 
T2) was evaluated using stepwise forward multivariable logistic 
regression analysis. This was used to select a panel of biomarkers 
from season 1 data (training dataset) to combine in a predictive 
algorithm using the logit function (intercept+β1Χ 1+ β2Χ2…+ 
β14Χ14, where β is the unstandardised beta weight and Χ is the 
measured concentration for the biomarker), and calculate the 
predicted probability (e∧logit/(1+e∧logit)) and group member-
ship (cut- off point ≥0.5 probability for concussion) for each 
player. The algorithm was subsequently prospectively tested on 
the independent season 2 data (test dataset) by replacing Χi with 
the new biomarker concentration values and blindly calculating 
predicted probability and group membership for each player. 
Goodness of fit was confirmed with the Hosmer- Lemeshow 
test. Accuracy was determined by measuring the AUC of the 
predicted group membership against the actual membership for 
the combined panel. Demographic data (age, height, weight) 
were then included in the regression model as covariates.
Target prediction and KEGG pathway analysis
To evaluate the plausibility of the microRNA biomarkers identi-
fied by this analysis, their biological targets and Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) pathways were assessed 
using the mirPath v.3 tool on DIANA tools via microT- CDS 
(v5.0) prediction,33 and selecting the following criteria: false 




Across the two seasons 393 HIAs were conducted in 184 players. 
Samples from 47 HIAs on 28 individual players were excluded as 
either ineligible or after independent review of the HIA records 
and video footage. Following clinical assessment, concussion was 
confirmed (HIA+) in 106 players and ruled out (HIA−) in 50. 
Compliance was 56% in both seasons.
Biomarkers identification
Next generation sequencing and data reduction
In season 1, NGS identified 38 known microRNAs, 233 putative- 
miRs (put- miR) and 168 other small RNAs as being differentially 
expressed at T2 between HIA+ samples and MSK/uninjured 
control samples (online supplemental material eTable 1).
HIA+ samples were then compared with HIA−, uninjured 
and MSK groups at different time points, as well as baseline 
samples, using qPCR. The initial analysis included 193 samples. 
Based on the strength of discrimination of concussed subjects, 
32 known microRNAs, 34 put- miRs and 28 other small- RNAs 
were selected for further analysis in 376 further samples (ie, 569 
samples in total). Of the 94 sncRNAs, 31 had >30% missing 
values and were removed. Among the remaining 63 sncRNAs, 
listed in online supplemental material eTable 2, the percentage 
of missing data was low (mean 3.2%, median 0%). These were 
used for statistical comparisons between the different groups 
and time points. A heat map representing the average value of 
the concentrations of the sncRNAs across different groups and 
sample time points is shown in figure 2.
sncRNA qPCR data analysis in season 1.
A large number of sncRNAs were significantly over- or under-
expressed in concussed players compared with the other groups, 
at all post- injury time points, with several members of the let-7 
and RNU6 families standing out in this analysis. The results are 
illustrated diagrammatically in figure 3. Let- 7f- 5p presented the 
highest AUC (0.89) and p value <0.001 at both time points T2 
and T3.
The full data on AUC, CI, count, ΔCq (mean±SD), ΔΔcq, fold 
change, t- test p value and power analysis for each comparison of 
individual biomarkers at time point T1, T2 and T3 are provided 
in the supplementary material (online supplemental material 
eTable 3–6).
Biomarker time course
Thirty- two different biomarkers were identified as differentially 
expressed between HIA+ and HIA− groups when compared 
at T1, T2 and T3 (online supplemental eTable 3–5). These 32 
biomarkers were longitudinally evaluated across the different 
time points with reference to their baseline values. In the 
concussed group, as shown in figure 4, there was significant 
interaction of several biomarkers with time from injury, with 
14 sncRNAs overexpressed and five underexpressed following 
concussion with respect to baseline values. The greatest effect 
of time (p<0.001) was found for let- 7a- 5p, let- 7f- 5p, miR-107, 
miR- 148a- 3p, miR- 135b- 5p, miR-21- 5p, miR- 34b- 3p, miR- 
103a- 3p and RNU6-45, which were overexpressed, and 
miR-1246, which was underexpressed. Conversely, in the HIA− 
group the biomarkers remained much closer to their baseline 
values throughout all time points after injury.
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Biomarker validation and predictive model 
sncRNA qPCR data analysis in season 2
To validate the candidate sncRNAs prospectively, 137 saliva samples 
were analysed by qPCR in season 2. Although the sample size of 
season 2 was smaller, several biomarkers found to be differentially 
expressed between groups in season 1 were confirmed to be statis-
tically significantly different across the same comparisons. Results 
are reported in online supplemental eTables 3–5. Let- 7f- 5p was 
confirmed as discriminating between HIA+ and HIA− (p=0.007) 
with an AUC of 0.80 (95% CI 0.62 to 0.97) at 36–48 hours only.
Multivariate predictive model performance
The logistic regression analysis identified 14 biomarkers (let- 
7a- 5p, miR-143- 3p, miR- 103a- 3p, miR- 34b- 3p, RNU6-7, 
RNU6-45, Snora57, snoU13.120, tRNA18Arg- CCT, U6-168, 
U6-428, U6-1249, Uco22cjg1 and YRNA_255) as offering the 
highest accuracy. The algorithm of the combined 14- biomarker 
panel showed accuracy of 0.91 (95% CI 0.81 to 1, p<0.001) at 
differentiating concussion (HIA+) from other groups (HIA−, 
uninjured and MSK combined) at T2 (figure 5 and online supple-
mental eTable 7) in the training dataset.
When prospective tested on season 2 (test dataset), the algorithm 
was highly accurate in classifying HIA+ from controls (HIA−, 
uninjured and MSK combined) at T2 (AUC 0.96, 95% CI 0.92 
to 1, p<0001) and T3 (AUC 0.93, 95% CI 0.86 to 1, p<0.001). 
Summary statistics for the 14 biomarkers are presented in online 
supplemental eTable 8. The inclusion of demographic data in the 
model showed no evidence of multicollinearity.
Figure 2 Heat map representing the average value of the concentrations of the miRNAs across different groups. Hierarchical clustering was 
performed across groups and miRNAs to check the similar behaviour of the miRNAs. HIA, head injury assessment; MSK, musculoskeletal.
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Target prediction and pathway analysis
KEGG pathway analysis was performed using the microRNAs 
identified in the comparison HIA+ vs HIA− at T1, T2 and T3. 
The pathway analysis revealed a strong association between let-7 
family members and the extracellular matrix (ECM) receptor 
interactions pathway, as well as a strong relation between miR- 
103a- 5p and miR-107 and fatty acid metabolism/biosynthesis. 
The full results are presented in online supplemental eFigures 
1, 2 and 3.
DISCUSSION
Current evaluation of sport- related concussion is largely based 
on the reporting of symptoms. Biomarkers are not used in this 
field at present but may prove useful for corroborating the 
diagnosis. In this study, we sought to investigate the role of sali-
vary sncRNAs as a new class of molecules to serve as poten-
tial biomarkers of sport- related concussion. We assessed these 
against a standard tool used to diagnose concussion in profes-
sional rugby. It is important to note, however, that biomarkers 
are the expression of biological changes, which may correlate 
with clinical outcomes, just as clinical outcomes may be reason-
able proxies for underlying biological changes, but that these are 
not replacements for each other.
We identified 32 different sncRNAs across three time points 
that were differentially expressed in rugby players with a clin-
ical diagnosis of concussion compared with those cleared of 
concussion after examination. In particular let- 7f- 5p offered 
good discrimination between HIA+ and HIA− (AUC 0.89 in 
season 1 and AUC 0.80 in season 2) at 36–48 hours. We also 
identified significant dynamic changes in the concentration of 
sncRNAs between time points post- concussion, suggesting that 
the biological response to injury evolves rapidly, as far as sncRNAs 
and the cellular processes that these post- transcriptionally regu-
late are concerned.
Finally, the key finding of this study was the identification of 
a panel of 14 different biomarkers that accurately predicted clin-
ical diagnosis of concussion in professional rugby players (with 
an AUC of 0.96 for the classification of HIA+ from controls 
immediately post- game), when prospectively tested on indepen-
dent data.
Taken together, sncRNAs have the potential to provide insight 
into pathophysiological responses in concussion and to be poten-
tially clinically useful in the diagnosis of concussion.
The biological plausibility of the biomarkers is corroborated 
by the notion that among the identified biomarkers, several have 
previously been associated with concussion/TBI or related pathol-
ogies, such as mir-21, an anti- inflammatory regulator, playing 
crucial role in the central nervous system34–36; miR-144, which 
promotes β-amyloid accumulation by suppressing ADAM10 
expression37; miR-1246 recently described as potential candi-
date of concussion21; miR- 135b- 5p previously identified by 
our group as salivary biomarker of concussion19 and the let-7 
Figure 3 Plots of comparisons between players with a head injury (HIA+; n=106) and non- concussed groups (uninjured (n=102), HIA− (n=50) and 
musculoskeletal (n=66) groups)) at all time points. The y- axis represents the area under the curve (AUC) and the x- axis the log 2 expression of fold 
change of significantly differentially expressed sncRNAs between HIA+ and the other groups at each time point. The colour identifies the p values of 
the t- test analysis of each sncRNA (red ≤0.001, green ≤0.01 and >0.001, and blue ≤0.05 and >0.01). The full analysis results (AUC, CI, count, ΔCq 
average, SD, ΔΔcq, fold change and t- test p value) are available in the online supplemental materials. MSK, musculoskeletal; sncRNAs, small non- 
coding RNAs.
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Figure 4 Longitudinal analysis. Thrty- two biomarkers selected as differentially expressed in the comparison HIA+ versus HIA− were used for 
the longitudinal analysis. Analysis of variance was performed in HIA+ and HIA− groups over time (T1, T2 and T3) and compared with baseline. 
Comparisons across multiple time points were evaluated using post- hoc Tukey’s honestly significant difference test. *Significantly different from 
baseline p<0.05; **significantly different form baseline p<0.001. HIA, head injury assessment.
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family, including let- 7i- 5p, let- 7b, let- 7a- 3p, let- 7c- 5p,19 22 23 38 39 
which is an important family of neuroinflammatory modulators 
showing an involvement in Alzheimer’s disease and in major 
depressive episodes.40 41 Bioinformatically, we showed a strong 
association between let-7 family members and the ECM receptor 
interactions pathway. Changes in levels of members of the let-7 
family were reported in previous studies in concussion, and 
integrity and changes in the ECM have been observed in brain 
injury,42 and other neuropathologies.43 Another strong relation 
between miR- 103a- 5p and miR-107 and fatty acid metabolism/
biosynthesis was also evident. This is intriguing, as a shift from 
glucose to fatty acid metabolism has been described in the tran-
scriptomic response to mild TBI.44 These initial findings highlight 
the potential for sncRNAs in developing a greater understanding 
of the pathophysiological response to concussion.
SncRNAs are stable and straightforward to assess. In addi-
tion, the choice of saliva as a non- invasive fluid allows for rapid 
and well- tolerated pitch- side and post- game collection at very 
early and specific time points. It is proposed that saliva can 
receive exosomal miRNAs directly from cranial nerves in the 
oropharynx, and as such there is a rapid response within saliva 
after TBI, making them particularly suitable for a pitch- side 
diagnosis.45 The development of point- of- care testing for sali-
vary sncRNAs would offer the prospect of a test for concussion 
that can support clinical decision- making in sport.
Strengths and limitations
It is important to note that although the number of players 
recruited to participate in the study is over 1000, the number of 
players who are regular starting players in each team, exposed 
to potential concussions every week, is much smaller. Therefore, 
a small number of players appeared more than once in different 
groups or less frequently in the same group. This can positively 
or negatively affect the magnitude of group differences.
Including uninjured players and players with musculoskeletal 
injuries as controls avoids the pitfalls of some previous biomarker 
research by ruling out the possibility that putative concussion 
biomarkers may come from other sources. We also analysed 
the baseline preseason samples of cases and controls to account 
for the potential influence of pre- existing factors. This led to 
the selection of a narrow panel of sncRNA biomarkers that are 
likely to represent a true signature of concussion. As sncRNAs 
appear to act in a concerted manner, analysis of multiple inter-
acting pathways is likely to provide a more accurate description 
of the response to a specific insult than individual biomarkers. 
This adds complexity when constructing a test, with an inherent 
risk of overfitting when testing multiple possible combinations. 
We sought to reduce the risk of overfitting by confirming the 
expression of our biomarkers across independent datasets from 
two separate seasons.
The study benefitted from not using a selected sample but 
instead recruiting all available players who were exposed to 
head injury with the potential to result in concussion from 22 
of 24 of the clubs participating in the top two tiers of English 
professional rugby. On the basis that participation was voluntary, 
and given the complexity of carrying out research procedures 
in a competitive sport environment, we were pleased with the 
overall 56% compliance. However, we cannot ascertain whether 
the remaining incidents were missed at random or systematically 
and how the results might have changed if samples had been 
Figure 5 Receiver operating characteristic curve results for a panel of 14 combined small non- coding RNAs differentiating players with confirmed 
concussion after the head injury assessment (HIA+) from other groups, including players who underwent a head injury assessment but had 
concussion ruled out (HIA−, orange line); Uninjured players from the same game who played a comparable number of minutes to those of the HIA 
players (uninjured, green line); players who were removed from the game due to musculoskeletal injuries (MSK, blue line); HIA−, uninjured and MSK 
groups combined (all combined, black line); and preseason values for concussed players (baseline, red line). The curves are shown for all time points 
(T1=during the game; T2=immediately after the game), and T3=36–48 hours after the game). Season 1 represents the training dataset and season 
2 the test dataset (HIA+, HIA−, uninjured and MSK groups, as well as HIA−, uninjured and MSK groups combined) for the logistic regression model. 
Samples were not collected during the game in season 2.
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included from these. For the clinical translation of the study, we 
would of course expect compliance to be much higher if these 
procedures were formally a part of a concussion management 
plan, as opposed to a research protocol.
The HIA protocol, used here as the current operational 
‘gold standard’ for the diagnosis of concussion in elite rugby 
union, provides the clinical outcome comparison for the assess-
ment of the biomarkers. The standardised clinical assessment, 
diagnosis and reporting of concussion by team physicians 
specifically trained in the application of the HIA protocol, 
with subsequent independent review of all cases, provides a 
high standard of clinical evaluation of concussion, plausibly 
explaining the good concordance between clinical diagnosis 
and biomarker expression. It is clear that in this study design 
the biomarkers cannot outperform the clinical assessment. As 
a consequence, we believe the biomarkers are likely to prove 
most useful in non- professional sport settings, where the over-
whelming majority of sport- related concussions occur. In these 
settings, access to trained healthcare professionals is limited 
both during and after the game and it is recommended that 
the presence of a single symptom or sign of concussion in the 
context of a head injury should result in concussion being 
suspected.
Finally, a limitation of the study is that it includes only male 
elite players, which could potentially affect the generalisability 
of its findings.
CONCLUSION: IMPLICATIONS FOR THE FIELD
The detection of signatures of concussion at early time points in 
saliva (a non- invasively sampled biofluid) presents both at the 
pitch side, and in primary care and emergency medicine depart-
ments, an opportunity to develop a new and objective diagnostic 
tool for this common clinical presentation. In addition, sncRNAs 
may be an important tool in developing understanding of the 
pathophysiology of concussion.
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Summary box
What are the findings?
 ► This study, conducted in a professional contact sport setting, 
has identified and prospectively validated both single 
candidates and a panel of small non- coding RNA salivary 
biomarkers of concussion.
 ► Let- 7f- 5p could distinguish players with confirmed concussion 
from those for whom concussion was subsequently ruled out 
after structured head injury assessments with an area under 
the curve (AUC) up to 0.89 at 36–48 hours from injury.
 ► A combination of 14 salivary biomarkers was highly accurate 
(AUCs 0.96 immediately post- game and 0.93 at 36–48 hours 
post- game) at identifying concussed players from all other 
groups, including players with suspicion of traumatic brain 
injury who had a concussion ruled out after a structured head 
injury assessment, uninjured controls from the same game 
and players who had had musculoskeletal injuries.
How might it impact on clinical practice in the near 
future?
 ► The biology of concussion is still not fully understood. Small 
non- coding RNAs provide further insights into the response 
to injury as this evolves from immediately after the event to 
several hours later.
 ► Concussion can be hard to diagnose and is often missed, 
especially where a structured evaluation by an expert 
clinician is not possible—for example, at grass- root level. 
Small non- coding RNAs can provide a diagnostic tool that 
might reduce the risk of missing this type of injury at all 
levels of participation.
 ► In community sport, salivary small non- coding RNAs may 
provide a non- invasive diagnostic test that is comparable in 
accuracy to the level of assessment available in a professional 
sport setting.
 ► At an elite level of participation, this diagnostic tool may 
become an adjunct to current head injury evaluation 
protocols.
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Two ml of saliva was passively collected from all subjects at clubs competing in the top two 
tiers of male Rugby Football Union in England across the 2017-18 (Premiership and 
Championship clubs) and 2018-19 (Premiership clubs only) seasons. Samples collected pre-
season were used as baseline.  During the season, samples were collected when club medical 
staff assessed players for concussion following head injury events with the potential to result 
in concussion using the standardised World Rugby Head Injury Assessment (HIA) protocol. 
[1] The key features of the protocol, that is in widespread use in elite professional rugby, are 
mandatory standardised assessments, aligned with the Sports Concussion Assessment Tool 
(SCAT5) at three time points informing a team physician’s clinical diagnosis. A definitive 
diagnosis of concussion is made if a player demonstrates observable signs of concussion at the 
time of the head injury event, requiring immediate and permanent removal from play (e.g. loss 
of consciousness, tonic posturing or ataxia) or a clinical diagnosis of concussion is made 
supported by the standardised (SCAT5) assessment performed post game and/or 36-48 hrs 
later. The interpretation of the SCAT5 assessment is with reference to individual baseline 
values and any negative deviation from baseline performance is recommended as strongly 
suggestive of a diagnosis of concussion, though the clinical judgment of the team physician 
takes precedence over the performance in the SCAT5 assessment.  If the defined observable 
signs of concussion are nor clearly seen following a witnessed head injury event however, and 
the diagnosis of concussion is uncertain, a player may be temporarily substituted to allow for 
a standardised in match but off field assessment to be conducted by the team physician. If 
concussion is then excluded by the team physician, there is an ability for the player to return to 
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play. World rugby rules required this assessment to be completed within 10 minutes, but a 
special dispensation was given for an extension of 3 minutes to permit study procedures to be 
carried out as part of the protocol for the current study in season 1. 
 Annual mandatory training programmes must be undertaken by all medical staff involved in 
the delivery of the HIA protocol. Formal audit, governance and disciplinary processes are in 
place to monitor compliance. All assessments are entered by team medical staff in real-time on 
an app (CSx) (https://csx.co.nz/our-story/) and are available for subsequent audit and review.      
The HIA protocol incorporates a very clearly defined and replicable definition of what 
constitutes a sport-related concussion and provided the diagnostic reference for our analysis. 
For the purpose of this study, we defined the in-match  assessment as time point T1, the post-
match assessment as time point T2  and the 36-48 hour assessment as time point T3. 
Participants who were evaluated using the HIA protocol formed the HIA+ group if concussion 
was confirmed at any of the three time points, and the HIA- group if concussion was initially 
considered but subsequently ruled out.  
Whenever a participant was assessed post-match (T2) for possible  concussion, team medical 
staff were asked to identify another participant who had played a similar number of minutes in 
the same match but who had not had been assessed for concussion and, if possible, a third 
participant who had had to be withdrawn from that match due to a musculoskeletal injury. 
Samples were requested from all categories of player at near enough the same time after the 
final whistle and were completed before players finished getting showered and changed. 
These provided samples at time points T2 and T3, to form the uninjured and the 
musculoskeletal Injury (MSK) control groups respectively. 
The HIA-T2 assessment was usually carried out between 30-90 minutes after the match 
finished for the player. Therefore, the range of HIA-T2 assessments was from 30 minutes 
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through to 190 minutes (90 minutes+80 minutes playing time+20 minutes interval) post injury 
if a player was removed in the first or completed last minute of the game respectively. 
It is also important to note that not all players had an assessment at time point T1, as not all 
significant head injury events are identified in game and symptoms for some players only 
develop post-game. Moreover, it would have not been possible to obtain samples from the 
uninjured group during the match, therefore, it was predetermined in the study design that T2 
would be the primary time point of interest for comparisons, as this would provide the most 
consistent timeframe to collect saliva samples across all groups.  
Although team physicians were responsible for the clinical management of each player in real-
time, in order to ensure a consistent diagnostic standard for the study, the full HIA protocol 
documentation for each player assessed for concussion and (where available) the video footage 
of the inciting head injury event were subsequently reviewed independently against the HIA 
protocol by two experienced sports medicine doctors and England Senior National Team 
doctors (SPTK and RT). They were blinded to any laboratory results and adjudicated each 
incident as HIA+ or HIA- or recommended its exclusion due to insufficient or conflicting 
evidence. For completeness, the analysis of the uncensored data is presented in this section. 
Saliva collection 
Medical staff at the respective clubs were trained in the collection procedure. Saliva was 
collected in Oragene®-RNA RE-100 saliva self-collection kits (DNA Genotek) containing an 
RNA stabilizing solution preserving the samples for up to 8 weeks. Saliva was collected from 
each participant at enrolment and at the time points described above. Samples were transported 
to the lab in Birmingham, where they were processed in line with the manufacturer’s protocol 
for storage. During the second season, DNA Genotek discontinued the RE-100 kits and 
replaced them with an equivalent product (CP-190). This was utilised from January 2018 
onwards. 
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NGS procedure  
Library preparation and Next Generation Sequencing 
Library preparation was carried out using the QIAseq miRNA Library Kit (QIAGEN). A total 
of 5ul total RNA was converted into microRNA NGS libraries. Adapters containing UMIs 
were ligated to the RNA. Then RNA was converted to cDNA. The cDNA as amplified using 
PCR (22 cycles) and during the PCR, indices were added. After PCR the samples were purified. 
Library preparation QC was performed using either the Bioanalyzer 2100 (Agilent) or 
TapeStation4200 (Agilent). Based on quality of the inserts and the concentration measurements 
the libraries were pooled in equimolar ratios. The library pool(s) were quantified using the 
qPCR ExiSEQ LNA™ Quant kit (Exiqon). The library pools were then sequenced on a 
NextSeq500 sequencing instrument according to the manufacturers instructions (NEBNext 
Multiplex Small RNA Library Prep Set for Illumina) to make approximately 163-175 base-pair 
sized libraries. Raw data as demultiplexed and FASTQ files for each sample were generated 
using the bcl2fastq software (Illumina inc.). FASTQ data were checked using the FastQC tool 
(http://. bioinformatics.babraham.ac.uk/proeects/fastqc/). 
Mapping 
A reference profile of sequencing data for each sample was obtained using the whole human 
genome sequence GRCh37, downloaded from the Genome Reference Consortium and 
mirbase_20 as an annotation reference. Reads were aligned to the miRbase using Bowtie2.[2] 
The mapping criteria for aligning reads to spike-ins, abundant sequence and miRBase were the 
reads to have perfect match to the reference sequences. For mapping to the genome, the 
restricting was one mismatch which was allowed in the first 32 bases of the read. No in-dels 
were allowed in mapping.  Unaligned reads were mapped against the host reference genome 
and used as input for mirPara [3] and miRbase to predict putative miRNAs. [4,5] 
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Statistical analysis 
P-values for significantly differentially expressed sncRNAs are estimated by an exact test on 
the negative binomial distribution. Aligned reads were counted and differential expression 
analysis, p-values for significantly differentially expressed microRNAs and false discovery 
rate according to Benjamini-Hochberg were performed with EdgeR.[6] For normalisation, the 
trimmed mean of M-values (TMM) method based on log-fold and absolute gene-wise changes 
in expression levels between samples was used.  
qPCR season1  
14 μl RNA was reverse transcribed in 70 μl reactions using the miRCURY LNA RT Kit 
(QIAGEN). cDNA was diluted 50 x and assayed in 10 μl PCR reactions according to the 
protocol for miRCURY LNA miRNA PCR; each miRNA was assayed once by qPCR on the 
miRNA Ready-to-Use PCR, custom panel using miRCURY LNA SYBR Green master mix. 
qPCR Probes are the complementary sequences of the sncRNAsof interest (eTable 2 below). 
Negative controls excluding template from the reverse transcription reaction was performed 
and profiled like the samples. The amplification was performed in a LightCyclerp 480 Real-
Time PCR System (Roche) in 384 well plates. The amplification curves were analysed using 
the Roche LC software, both for determination of Cq (by the 2nd derivative method) and for 
melt curve analysis. The amplification efficiency was calculated using algorithms similar to 
the LinReg software. All assays were inspected for distinct melting curves (Tm) and the Tm 
was checked to be within known specifications for the assay. Furthermore, assays must be 
detected with 0 Cq less than the negative control, and with Cq<37 to be included in the data 
analysis. Data that did not pass these criteria were omitted from any further analysis. Cq was 
calculated as the 2nd derivative. Normalization was performed based on the average of hsa-
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miR-29c-3p and hsa-let-7b-5p (custom normalizer assays), the two most stable miRs identified 
across all samples by Normofinder software.[7] 
The formula used to calculate the normalized Cq values is the difference between the custom 
normalizer assays mean Cq and the assay Cq (miRNA of interest). After normalization 20 has 
been added to the normalized dCq values to shift the numbers in a positive range to allow using 
the qPCR analysis pipelins according Qiagen procedures. While processing the data in the 
qPCR pipeline a minus is inserted before the normalized dCq value. A higher value indicates 
that the miRNA is more abundant in that sample. 
qPCR season 2 
RNA from saliva samples was extracted and analysed with exactly the same protocol used for 
SCRUM1 and qPCR was performed using the Applied Biosystems Quantstudio 5 
(ThermoFisher Scientific) for amplification and melt curve analysis. 
 
 
ADDITIONAL ANALYSIS RESULTS 
 
NGS and qPCR data analysis 
The validation was performed in 2 different qPCR steps. Initially, all fragments showing a 
different expression between HIA+ T2 and MSK+uninjured T2 groups in NGS analysis 
(eTable1), were selected for the first qPCR validation step. This list, comprising 38 known 
microRNAs, 233 put-miRs and 168 other small RNAs, was analysed in 193 samples. Following 
this initial analysis, based on the strength of discrimination of concussed subjects, we selected 
32 known microRNAs (panel A); 28 other small RNAs (panel B) and 34 put-miRs (panel C) 
for further analysis in 376 independent samples The Cq values obtained from the 2 qPCR 
validation sets were finally merged and collected in a total of 569 samples. Of the 94 sncRNAs, 
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31 had >30% missing values and were removed. The remaining 63 sncRNAs (comprisinf og 
23 microRNAs, 11 putative microRNAs and 29 other small non-coding RNAs) are listed in 
eTable2  and were used for statistical comparisons between the different groups and  time 
points (eTable 3,4,5,6). 
The power analyses indicating how many samples are needed per group in a follow-up study 
to validate the results from the present analysis was calculated at a 0.95 level of confidence 
and for target p-value 0.05. 
 
eTable 1: List of microRNAs (Panel A), other small non-coding (Panel B) and putative* 
microRNAs selected from NGS analysis. 
*putative microRNAs are not previously described sequences and bioinformatically predicted 
as new microRNAs 
Panel A 
microRNAs logFC logCPM p-Value FDR 
hsa-miR-199a-5p -3.79380184 5.744164606 8.15823E-06 0.004797041 
hsa-miR-133a-3p -4.95698696 10.40020121 7.04586E-05 0.020714819 
hsa-miR-206 -4.6959152 9.788488822 0.000180043 0.03528849 
hsa-miR-1273h-3p 2.629420889 3.481729832 0.001297451 0.190725263 
hsa-miR-133b -4.20181151 6.465178373 0.002184888 0.256942851 
hsa-miR-561-5p 1.579551555 4.525850808 0.003970504 0.348018465 
hsa-miR-126-3p -1.41838668 8.449681001 0.004143077 0.348018465 
hsa-miR-16-1-3p 1.43849327 4.458454478 0.005764959 0.352449414 
hsa-miR-449b-3p 3.467958972 3.218975 0.005920497 0.352449414 
hsa-miR-449c-5p 2.749952622 5.534179256 0.006033974 0.352449414 
hsa-miR-6748-3p 4.143101791 3.188086662 0.007073212 0.352449414 
hsa-miR-133a-5p -3.92797466 4.752927061 0.008472679 0.352449414 
hsa-miR-34b-3p 2.1437498 4.339967792 0.008637715 0.352449414 
hsa-miR-6824-3p 2.731145621 3.076936275 0.008970282 0.352449414 
hsa-miR-5195-5p 5.376105018 4.09767258 0.009313959 0.352449414 
hsa-miR-5096 2.906908779 4.723794715 0.00959046 0.352449414 
hsa-miR-4488 3.491520052 3.097320079 0.012515423 0.409279535 
hsa-miR-92a-3p -0.60902412 10.49283489 0.012885103 0.409279535 
hsa-miR-1 -2.36876254 10.80951287 0.013692259 0.409279535 
hsa-miR-885-5p 1.507019382 4.182851751 0.013921073 0.409279535 
hsa-miR-548h-5p 2.055544755 3.480848725 0.015148132 0.42414769 
hsa-miR-1246 0.980484408 14.78271469 0.017085283 0.445746733 
hsa-miR-4492 -3.18487947 3.53612341 0.017435672 0.445746733 
hsa-miR-484 1.274418725 6.148369199 0.019071294 0.449461809 
hsa-miR-449a 2.203777576 6.338766334 0.019109771 0.449461809 
hsa-miR-3122 3.142476669 3.078975177 0.02000366 0.452390465 
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hsa-miR-1180-3p 1.165471248 3.889331639 0.021316281 0.457201951 
hsa-miR-619-5p 2.792045377 3.207604869 0.021771521 0.457201951 
hsa-miR-2277-5p 1.067026052 4.057818901 0.023836409 0.474930011 
hsa-miR-5699-3p 1.876788488 2.955683933 0.024231123 0.474930011 
hsa-miR-125b-2-3p -0.96587973 4.933520984 0.025679562 0.487083301 
hsa-miR-4449 2.06863176 3.047374886 0.027679506 0.503997815 
hsa-miR-671-3p 1.125735449 3.934232773 0.02867908 0.503997815 
hsa-miR-33a-3p 0.959071217 4.091785492 0.029142731 0.503997815 
hsa-miR-193b-5p -1.14025756 4.138245693 0.031271072 0.522692794 
hsa-miR-34c-3p 1.690242737 4.489423918 0.0320016 0.522692794 
hsa-miR-339-5p 1.057419584 7.902671962 0.034354837 0.545963351 
hsa-miR-6813-3p 2.813650185 2.933287004 0.035310016 0.546376034 
hsa-miR-671-5p 0.838663749 5.600518309 0.047339286 0.598988904 
hsa-miR-1537-5p 1.129462606 4.117629615 0.048138455 0.598988904 
hsa-miR-193a-3p -1.5845588 3.995294293 0.048897053 0.598988904 
hsa-miR-130a-3p -0.88824466 6.580760266 0.051263632 0.604409433 
hsa-miR-126-5p -1.22112275 8.006357503 0.051621005 0.604409433 
 
  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103274–10.:10 2021;Br J Sports Med, et al. Di Pietro V
   
 
   
 
Panel B 
small non-coding RNAs logFC logCPM p-Value FDR 
tRNA138-ArgACG -2.27538237 7.674009775 0.000243882 0.204980883 
RNU6-11 -1.67718785 4.732492163 0.000245185 0.204980883 
tRNA11-ArgACG -2.21044709 7.59261144 0.000408122 0.204980883 
RNU6-36 -1.84798113 4.63862015 0.000436362 0.204980883 
tRNA175-SerGCT -1.84762954 8.390549302 0.001054009 0.290869197 
U3.39 4.655316415 4.424357984 0.001147835 0.290869197 
RNU4-6P -1.71160894 4.864935322 0.001317818 0.290869197 
U6.375 -1.86391998 4.231358228 0.001366655 0.290869197 
snoU13.63 4.286830869 4.29762358 0.001552935 0.290869197 
tRNA8-ThrAGT -1.65324248 9.428427256 0.001556007 0.290869197 
RNU6-1 -1.37118776 4.843026936 0.001713194 0.290869197 
RNU6-31 -1.53604238 4.741724921 0.002351551 0.290869197 
tRNA4-ArgTCG -1.70070174 10.2139807 0.002452994 0.290869197 
tRNA130-ValCAC -2.21562973 4.853113645 0.002797565 0.290869197 
U3.3 -1.72401526 5.267608648 0.002991025 0.290869197 
U4.57 -1.55456476 4.807782758 0.003084965 0.290869197 
tRNA84-GluTTC -1.39818637 10.32369425 0.003223874 0.290869197 
U6.428 -1.83108856 4.169870903 0.003289229 0.290869197 
U3.4 -1.80036039 5.421618508 0.00346512 0.290869197 
tRNA95-AsnGTT -2.24304788 4.752212371 0.003469246 0.290869197 
uc003oif.3 -2.59243747 4.028384043 0.003838286 0.290869197 
U3.2 -1.73251154 5.414684824 0.003880282 0.290869197 
U3.42 2.126244843 4.003126274 0.003910676 0.290869197 
uc002tgp.1 2.810368883 4.510093789 0.004221387 0.290869197 
tRNA105-PseudoTTC -1.59015632 7.983774255 0.004475105 0.290869197 
tRNA4-GluCTC -1.60952388 8.107675756 0.00453217 0.290869197 
RNU6-14 -1.86375965 4.058373711 0.004721183 0.290869197 
tRNA4-ThrAGT -1.34446936 8.68050744 0.004730298 0.290869197 
U6.97 -2.76317407 3.745083257 0.004815026 0.290869197 
tRNA120-AlaAGC -1.31815493 9.587766586 0.004875694 0.290869197 
snoU13.348 2.256666202 4.075754187 0.005036202 0.290869197 
U1.105 -2.32216301 4.207692971 0.005058512 0.290869197 
tRNA27-MetCAT -2.34782418 6.706470837 0.0051084 0.290869197 
U1.10 -2.59329176 4.816351388 0.005540106 0.306172302 
tRNA134-GluTTC -1.3431528 10.39664851 0.006091168 0.32697053 
RNU6-6 -1.54430018 4.19348578 0.00626447 0.32697053 
Y_RNA.75 1.904869354 5.50161645 0.006713926 0.340251318 
tRNA8-Undet 1.964251986 4.197405842 0.006905386 0.340251318 
SNORA25 -2.35025006 3.740784336 0.007062161 0.340251318 
RNU6-39 -1.60601357 4.333253034 0.007621329 0.3538182 
tRNA119-AlaCGC -1.25397272 9.514833568 0.007808074 0.3538182 
tRNA85-PseudoTTC 1.126764653 5.8624175 0.008322426 0.3538182 
U6.254 -1.80163898 3.954386151 0.008365638 0.3538182 
tRNA3-ArgCCT -1.40848109 10.46544955 0.008483646 0.3538182 
SNORD114-2 -3.1187271 3.929437693 0.008576479 0.3538182 
tRNA162-MetCAT -2.31337858 6.829504657 0.008700411 0.3538182 
Y_RNA.661 -2.13613309 3.924521406 0.008896949 0.3538182 
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tRNA8-AlaTGC -1.03417608 10.23229845 0.009262877 0.3538182 
tRNA56-ThrTGT -1.43137722 10.38511882 0.009580922 0.3538182 
tRNA26-AsnGTT -1.2260783 8.800207822 0.009587969 0.3538182 
tRNA73-ArgCCG -0.87676773 7.646480047 0.009603368 0.3538182 
tRNA156-ArgACG -1.38659506 6.417990561 0.009974671 0.36043089 
tRNA28-IleAAT -0.96475102 8.290575814 0.010463073 0.370945534 
RNU6-33 -1.41177741 4.713635974 0.010694162 0.372117242 
tRNA3-ProTGG 2.564031745 13.63247318 0.01106572 0.37247176 
tRNA19-ArgTCG -1.57386692 9.439040466 0.011100808 0.37247176 
tRNA164-MetCAT -2.24158666 6.824859219 0.011731788 0.372701442 
tRNA13-AlaCGC -1.05980195 9.619304583 0.011862589 0.372701442 
U6atac.4 -2.29659983 4.169967341 0.012205483 0.372701442 
tRNA9-AlaAGC -1.76859219 4.913678407 0.012206837 0.372701442 
tRNA132-PseudoCAC -2.28282945 4.122549605 0.012249051 0.372701442 
RNU6-7 -1.54429239 4.25135459 0.012297759 0.372701442 
tRNA20-MetCAT -1.09889413 8.557399735 0.012787128 0.376829052 
U3.24 -1.49142526 5.576968961 0.01283505 0.376829052 
U6atac.29 -2.38352866 3.785989635 0.013059629 0.377523747 
tRNA2-LeuTAA -1.66936742 3.974107686 0.013474016 0.383601155 
tRNA1-AsnGTT -0.93147558 7.962088764 0.014090452 0.39410967 
tRNA40-ThrAGT -1.20252417 8.00746198 0.014483817 0.39410967 
Y_RNA.684 2.380168702 3.849210771 0.014510103 0.39410967 
snoU13.86 3.047260829 3.887450563 0.014700195 0.39410967 
uc021qtn.1 -2.42558461 4.054546636 0.015164662 0.39410967 
RNU6-9 -1.27226823 4.707463894 0.01590456 0.39410967 
tRNA13-AlaTGC -1.07694323 9.510390292 0.016125256 0.39410967 
tRNA36-ArgACG -1.42222279 6.510745574 0.016234233 0.39410967 
Y_RNA.719 -1.87621292 4.049552581 0.016340695 0.39410967 
RNU6-10 -1.35736219 4.333057065 0.016389921 0.39410967 
SCARNA4 0.900162218 5.772147414 0.016691546 0.39410967 
tRNA10-AlaCGC -1.08617369 9.364295675 0.016698714 0.39410967 
tRNA12-SerAGA -2.17129695 3.960150632 0.016746309 0.39410967 
uc011ley.2 -1.1603733 7.787151849 0.01677955 0.39410967 
U1.116 -2.53057666 4.143384152 0.017351703 0.3975759 
tRNA7-SerGCT -1.22744148 8.048077286 0.017683906 0.3975759 
U6.266 -1.68215765 4.162672228 0.018006863 0.3975759 
tRNA136-AsnGTT -1.18546894 6.252578135 0.018057145 0.3975759 
uc031qaf.1 3.07982529 4.21672176 0.018100789 0.3975759 
RNU4-9P 1.971224737 3.892961999 0.018196662 0.3975759 
RNU6-48 -1.41494718 4.179417866 0.018610429 0.40194249 
U4.64 -1.46842052 4.573943777 0.019052174 0.405290215 
SNORA70.5 -2.3066839 3.705457206 0.019552672 0.405290215 
tRNA83-AsnGTT -0.95893311 7.650753844 0.019695599 0.405290215 
tRNA21-ArgCCT -1.3243702 9.463647642 0.019740822 0.405290215 
RNU6-26 -1.26772628 4.674223977 0.019843906 0.405290215 
tRNA4-AsnGTT -0.95216219 7.630343605 0.020477143 0.409060595 
U1.28 -1.66671858 4.666167958 0.020920233 0.409060595 
U6.168 -1.75957771 3.988195609 0.021394709 0.409060595 
RNU6-41 -1.2429829 4.599263654 0.021413125 0.409060595 
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tRNA15-ThrCGT -0.94643604 8.011751983 0.021715336 0.409060595 
tRNA88-PseudoCCT 1.406009411 4.775992477 0.021727046 0.409060595 
SNORD116-19 -2.08108498 3.769046556 0.022072958 0.409060595 
uc031qtw.1 -1.59586877 3.698957807 0.022111714 0.409060595 
U6.422 -2.18510267 3.771206474 0.022136152 0.409060595 
U2.3 -1.09052752 5.567176812 0.022205525 0.409060595 
U3.20 -1.55295135 5.225744713 0.022487766 0.410237987 
tRNA165-IleAAT -0.81674152 8.525161575 0.023067622 0.416176914 
snoU13.160 -1.88380693 3.690235583 0.023604159 0.416176914 
tRNA36-ThrAGT -1.09203025 7.99788872 0.023653935 0.416176914 
tRNA6-TrpCCA -1.06582891 10.59444161 0.023699271 0.416176914 
SNORA57 -1.08263716 5.14915277 0.024108905 0.416665441 
tRNA10-PseudoTGA -1.42087364 5.662435588 0.024173287 0.416665441 
uc001myu.3 -2.42408101 4.681561536 0.02449142 0.416665441 
Y_RNA.428 -1.2545658 6.369684888 0.024614084 0.416665441 
SCARNA1 -1.61719768 3.852134167 0.025631096 0.427567583 
tRNA95-AlaAGC -1.73027899 5.825175769 0.02592783 0.427567583 
RNU6-27 -1.6140049 3.926299889 0.025940769 0.427567583 
SNORA79.1 -1.15165538 4.196182085 0.026538748 0.433620064 
tRNA9-IleAAT -0.73350055 8.536774944 0.027547951 0.446033785 
tRNA9-TyrGTA -1.6487492 3.959996969 0.027773259 0.446033785 
tRNA23-ArgCCG -1.31033598 11.27930104 0.029044541 0.450180862 
snoU13.318 -1.91587082 3.698261411 0.029045067 0.450180862 
snoU13.328 2.684496203 4.280709032 0.029064976 0.450180862 
RNU4-4P -1.2311376 4.615863264 0.029137817 0.450180862 
Y_RNA.633 -1.30999509 4.118055921 0.029229412 0.450180862 
RNU5F-4P -1.48557387 4.239223966 0.03016703 0.460844298 
tRNA7-AsnGTT -0.88097126 7.861805832 0.031177808 0.472444358 
tRNA2-ArgCCT -1.14460252 9.768619156 0.031689267 0.476353057 
tRNA18-ArgCCT -1.24884324 9.421599432 0.032541851 0.484021239 
SNORD116-25 1.724675764 6.034751745 0.032861609 0.484021239 
uc021ybm.1 -0.9249247 7.924193472 0.033450576 0.484021239 
tRNA8-SerGCT -0.98753133 8.589816708 0.033481121 0.484021239 
tRNA11-IleAAT -0.72451906 8.545784821 0.033487366 0.484021239 
Y_RNA.597 1.732733959 3.760735382 0.034265836 0.491492414 
snoU13.120 2.312826375 3.740373282 0.034550843 0.491826017 
uc031qpu.1 2.324532842 3.768342356 0.035349099 0.49676233 
RNU6-32 -1.18812391 4.327815738 0.035426372 0.49676233 
tRNA100-PseudoGAA -1.02843913 9.329302032 0.036035102 0.501555229 
SNORD116-21 2.33201432 3.747426753 0.039146195 0.532853476 
tRNA5-IleTAT -1.08777911 7.207879458 0.039415342 0.532853476 
Y_RNA.522 -1.81515534 4.101934504 0.039799275 0.532853476 
tRNA12-ArgCCT -1.27295081 9.216801318 0.039946538 0.532853476 
U6atac.20 -1.94596283 4.036085302 0.040551585 0.532853476 
RNU6-4 -1.52406279 4.105411071 0.040667896 0.532853476 
SNORD3B-2 -0.79576357 8.540015612 0.040838684 0.532853476 
tRNA11-AsnGTT -1.30462038 4.970141103 0.040850618 0.532853476 
tRNA31-AsnGTT -0.87710624 7.603607761 0.041107699 0.532853476 
Y_RNA.727 -1.25639747 4.115195415 0.041225337 0.532853476 
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RNU6-73 -1.46456929 4.007858615 0.042069664 0.532853476 
SNORA65 -0.88817274 4.89950806 0.042220138 0.532853476 
tRNA7-LeuAAG -0.71492427 8.880350642 0.042319347 0.532853476 
tRNA144-AspGTC -0.82964134 11.54055138 0.042320413 0.532853476 
U6atac.25 -1.77774451 3.762252674 0.042537531 0.532853476 
tRNA1-ArgCCG -0.76847131 7.276226466 0.043525106 0.535998445 
SNORA7.4 -1.13362614 3.738511771 0.043665668 0.535998445 
tRNA125-ThrCGT -1.08045128 5.458664529 0.043842913 0.535998445 
RNU6-45 -1.22266691 4.217769003 0.043929622 0.535998445 
tRNA131-GlnCTG -1.07262477 7.700551934 0.04461864 0.538855811 
U6.1249 1.668615649 3.756761746 0.044737364 0.538855811 
Y_RNA.245 2.25187274 3.754483152 0.045943642 0.545496798 
U6.601 -1.35324491 3.970443965 0.046003943 0.545496798 
RNU5E-4P -1.0837447 5.498269856 0.046159655 0.545496798 
tRNA66-AlaTGC -0.81125784 9.226831102 0.046988475 0.545729532 
tRNA32-MetCAT -0.82679514 8.99856138 0.047086999 0.545729532 
U4.79 -1.25353509 4.433132105 0.047164353 0.545729532 
tRNA4-HisGTG -1.61899083 3.790696889 0.047553836 0.545729532 
U3.13 -1.51261982 3.797771351 0.047790048 0.545729532 
RNU6-5 -1.02972321 4.777615387 0.048416122 0.545729532 
SNORD36A -1.75616298 3.84054929 0.048459133 0.545729532 
tRNA1-LeuAAG -0.6699966 8.883794181 0.048648388 0.545729532 
RNU6-29 -1.13048434 4.36662749 0.048793274 0.545729532 
 
Panel C 
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logFC logCPM PValue FDR 
put-miR-718 TTCAGGTTACCGCAGG -6.825255 9.009089 1.21E-05 0.01609 
put-miR-594 TGATTTTTTTTGGCGAA -8.122089 13.62184 4.24E-05 0.028197 
put-miR-703 GACTGCTCGAGCTGCTT -4.582706 9.340091 0.000177 0.065276 
put-miR-477 TGGGCAGCAAGAATGG -6.350308 8.65459 0.00021 0.065276 
put-miR-727 GGAGGATTTCAATTGG -4.944239 7.848316 0.000246 0.065276 
put-miR-646 TCTGTCATGGCTGAGC -6.551056 8.808979 0.000322 0.065276 
put-miR-675 TACCTCAATTCTCTAGG 5.756095 8.531088 0.000387 0.065276 
put-miR-319 TGTCGGCGGGGGCCCCGGAC -3.557921 10.21937 0.000409 0.065276 
put-miR-327 CATTCTCTGAAACTACA -6.062301 8.473821 0.000441 0.065276 
put-miR-338 GACTTGTGATTAGCGG 5.013978 10.59887 0.000571 0.067661 
put-miR-1187 GAGCATGTTGACTGGAGA -6.150807 8.514764 0.000634 0.067661 
put-miR-6 GCGGACCTTGCTCAAGG 8.830503 11.10951 0.000659 0.067661 
put-miR-341 TGAGAAAACATTTGAGG -5.709943 8.260643 0.000661 0.067661 
put-miR-750 CAAGAGATGAGGAATG -5.585098 8.184314 0.000814 0.07204 
put-miR-183 CCAGGCTGGTCGTGATGA -5.716867 8.806919 0.000855 0.07204 
put-miR-980 TCGGAAGAAGAAGCTGACCCA -5.533531 8.158978 0.000866 0.07204 
put-miR-798 TAACTCTTGGAAATCTTGG -3.422593 9.962536 0.001016 0.075645 
put-miR-765 AAAAAAGAGGGACAGAAATG -5.173073 7.963608 0.001123 0.075645 
put-miR-71 GACCTTGGGTTGGGTCGTGGT -3.989796 8.732315 0.001131 0.075645 
put-miR-1327 GAAAAGCAATCGTCACAG -7.093524 9.887535 0.001158 0.075645 
put-miR-371 AATATTCAGCAGTCAGACTGG 6.778311 9.768186 0.001224 0.075645 
put-miR-354 CAGGGTGATGACTTCTG -4.795128 7.781813 0.001302 0.075645 
put-miR-688 GTGATGTCGGCTCATCGCAACCT 2.199185 10.66612 0.001307 0.075645 
put-miR-756 TGAGGGATGTTTGGATGCTCGCTTTGA 2.032426 8.603553 0.001428 0.079215 
put-miR-1146 CAACTGTAAGTCCATT 4.770832 9.196252 0.00158 0.079645 
put-miR-1333 TAATTGTCCTCTTGGGG -4.794112 7.786171 0.001619 0.079645 
put-miR-511 AAGCAGGCGTTACAATG -7.089632 9.54354 0.001631 0.079645 
put-miR-1199 TGAACTCGGGAGAAGGAAGT -2.994051 11.94621 0.001702 0.079645 
put-miR-705 CCTGTCTGACTGGGTCTCC 6.097356 9.460857 0.00175 0.079645 
put-miR-1275 AAGAAGTAGACTGGATTGG -4.175643 7.541711 0.001817 0.079645 
put-miR-1204 AGGGCTGGGCACGGGGG -3.329219 8.43806 0.00195 0.079645 
put-miR-857 TAAGTGGGAGTGCTCATG 5.519775 8.389269 0.001957 0.079645 
put-miR-806 CACGAGAGAACGCACACC 7.044016 9.996928 0.002048 0.079645 
put-miR-680 GTTAAGTATGCACAGG 6.207669 9.293799 0.002048 0.079645 
put-miR-576 TGGCATCCTGTCTCTTGC 5.455074 8.34397 0.002094 0.079645 
put-miR-444 CTGAAAAGGGGACGGATTGGGAA -4.481465 8.254479 0.002327 0.083951 
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put-miR-1132 CACGCTGTCTTTTGTTTCTCT -5.505609 11.5441 0.002357 0.083951 
put-miR-1025 TGGAAGAGGGGAAAGGAGA -4.492628 7.660657 0.002418 0.083951 
put-miR-496 CTAAGAGTATGAGTAGC 8.320903 10.63469 0.00246 0.083951 
put-miR-657 TCAGGACATTGGACTCT -4.875422 9.301419 0.002633 0.087604 
put-miR-625 GAGAAGACTGAATGCTCTTCTC 5.988262 8.702871 0.002699 0.087604 
put-miR-40 GCTGGAATAGCTCAGTTGC -4.339713 10.82143 0.00295 0.093474 
put-miR-666 CAGCATCATGATCATTATGG 6.351541 8.967721 0.003077 0.095259 
put-miR-1098 AAGGCGAAGGATATGTTG 7.117298 9.563651 0.003171 0.095916 
put-miR-538 CATTGTGCTTCGTGGGAGAGTAGGGCA -1.614431 8.767576 0.003422 0.101205 
put-miR-952 GCCGACAGGTCCGGGTAA -5.048736 10.09864 0.003556 0.101506 
put-miR-572 TAGATTCAGGAACTGCCA 7.280517 9.715353 0.003598 0.101506 
put-miR-972 TTTAGTAGAATTGTGTTGGGT -3.277557 9.430308 0.003661 0.101506 
put-miR-650 AAAAGCAAGGCGAAGAGG -2.912473 9.278157 0.003775 0.102538 
put-miR-134 CAGACTGCTCGAGCTGCTGC -3.339267 9.218851 0.003866 0.102908 
put-miR-975 TTTGCAGACTGGAAACT 5.625435 8.451316 0.004252 0.109356 
put-miR-161 TGTCTGTAGCAATGTGCT -6.214205 9.449224 0.004553 0.109356 
put-miR-1265 TGGGGATAAAGTTAGGT 3.433066 12.55135 0.004559 0.109356 
put-miR-968 TGGCTGTTGCACTTCT 8.03171 10.36384 0.004661 0.109356 
put-miR-1125 TTGAAGACTGGCTCTCA -4.530734 8.355286 0.00501 0.109356 
put-miR-892 CAACGGTCTTGAAAACA 3.239723 8.81171 0.005015 0.109356 
put-miR-1306 ATAACGTCATCTAGTGTG -4.744221 10.56016 0.005065 0.109356 
put-miR-948 TGGAAGAAAACGAGGAG 5.807023 8.569858 0.005204 0.109356 
put-miR-925 ATTTTGGTCTGTTGGTT 4.384338 8.643659 0.005342 0.109356 
put-miR-259 ATGTAACCGGGCTTTTGTGCT -1.786601 8.598848 0.005378 0.109356 
put-miR-209 GGTCCTCGGATCGGCC -4.053427 9.542155 0.005417 0.109356 
put-miR-773 CAGGCAGAAGGGAGCTTGT -2.64537 7.45467 0.005514 0.109356 
put-miR-910 CACGTTCTTCTCATGGT -3.449747 7.34067 0.00564 0.109356 
put-miR-664 AAAGTTGTGTTAGCTGA 5.719212 8.51182 0.005786 0.109356 
put-miR-1068 TATGATTGTAAACTCTGA 5.890866 8.622725 0.005843 0.109356 
put-miR-265 CACATGGGGGTAGAGCACTGACTGGG 2.110742 12.54113 0.005876 0.109356 
put-miR-490 CTGCAGGAGTGTTTGAGA 2.057932 11.07639 0.005969 0.109356 
put-miR-1155 CAAATGATCAAAGCAGG 2.494173 8.354137 0.006008 0.109356 
put-miR-893 ACCATCCTCTGCTACCA -2.575152 8.358309 0.006075 0.109356 
put-miR-1342 ATCGGAAAATGTGGGAA 5.585468 8.418657 0.006226 0.109356 
put-miR-967 AAATGCATTGGATATGG 7.085615 9.549591 0.006355 0.109356 
put-miR-811 GTTGTAAAGCTCTGTTG 1.99226 9.063173 0.006362 0.109356 
put-miR-812 GTTCTGAGTTCTTTGGTTGGA 7.523344 9.907158 0.006484 0.109356 
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put-miR-1084 AGGACCATTGCGTTGCC 6.454871 9.04042 0.006577 0.109356 
put-miR-626 TTCACTACTTTATCTCTTTT 2.849801 9.706572 0.006577 0.109356 
put-miR-127 AGACTGTGATGACTGGGAGAGCGGGCT -2.251745 7.719415 0.006585 0.109356 
put-miR-219 GAGGCTCGAGAGCAATGGC 4.972872 8.410708 0.006604 0.109356 
put-miR-863 AAGTTGGAGTATGTTTTAGG 4.174184 8.270046 0.006626 0.109356 
put-miR-33 CCATGACTGCAGATGG -4.437318 8.062018 0.006671 0.109356 
put-miR-1246 CTGGAGATCTGTTTGGGC 6.389535 8.993512 0.00675 0.109356 
put-miR-126 GTGGGGCTTAGTGCTGA -4.160086 8.05272 0.006849 0.109356 
put-miR-459 GGGATCAACCTGACAA 7.00545 9.47012 0.00689 0.109356 
put-miR-907 CCAACAGCTTCTGAGTTG -5.599664 9.28021 0.006923 0.109356 
put-miR-171 GTCCTGTGTCTTGTACGG 2.359948 10.86341 0.006942 0.109356 
put-miR-1163 AGAGGACAGGGAAGCTT 6.420538 9.017069 0.006996 0.109356 
put-miR-204 AGAAGTCAGAACCTCTAT 6.610111 9.154177 0.007138 0.109356 
put-miR-498 GACAGATTTTAGCTTGTCC 2.214527 8.621153 0.007148 0.109356 
put-miR-286 TAACAGGCGTTGAAATTGT 6.754071 9.266989 0.007468 0.112951 
put-miR-223 GATGGGGGTAGAGCACTGC 2.25836 12.07399 0.007601 0.113671 
put-miR-75 TGGGGATTGTGGGTTCTC -2.009287 9.598075 0.00774 0.114174 
put-miR-548 AGAGGACAGGGAAGCT 6.104866 8.784136 0.007923 0.114174 
put-miR-1118 AGAGGGTTCCTGTAGACCTAGGGAGGA -2.053777 10.22693 0.007925 0.114174 
put-miR-943 AGCCAGAGTTCTGATTGTGAGTG -4.954652 9.727141 0.007978 0.114174 
put-miR-313 TGAGTTCTTTGGTCAGAA 6.693723 9.211486 0.00821 0.114289 
put-miR-659 AGTAGCTGGTCGATTTGGC 6.996383 11.79431 0.008416 0.114289 
put-miR-210 CTTCAGACTGTGAAACTGA -2.997776 9.522779 0.008481 0.114289 
put-miR-144 TAGAGATAGAGCTTATG 5.529267 8.376117 0.008489 0.114289 
put-miR-563 TGGAGACATTAACTATGA 5.915791 8.643491 0.008604 0.114289 
put-miR-1140 TGGGAAGGGCTGCCGG -5.145788 9.310603 0.008606 0.114289 
put-miR-497 TTGGTAGACTCTCACTT -4.014605 9.04369 0.008664 0.114289 
put-miR-573 TGGATAACTCTTTTTGTA 6.440895 9.021507 0.008788 0.114289 
put-miR-906 TATGGGAAGAATCTGGG 6.054559 8.747883 0.008793 0.114289 
put-miR-231 TATGTCATGGTGGCTTTGG -2.9467 8.39848 0.008918 0.114289 
put-miR-85 GAATCCCACTTCTGACACCA -2.952626 7.663083 0.00901 0.114289 
put-miR-884 ATGGTCTAGAGCTACAGGT 5.870477 8.628199 0.00911 0.114289 
put-miR-918 CAGCTTCTTCCGCTTCTT 5.860051 8.60284 0.009174 0.114289 
put-miR-985 GTACTGCATCTCTGCA 5.898607 8.628545 0.009188 0.114289 
put-miR-320 ACTGGATCCAAGAAAAG -2.920156 8.226536 0.009571 0.11795 
put-miR-67 AGGACGTTGGTCAGAGC -2.895467 7.636799 0.009857 0.119419 
put-miR-221 TCTCTCAATCCTCTTGG 5.954163 8.658651 0.009869 0.119419 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103274–10.:10 2021;Br J Sports Med, et al. Di Pietro V
   
 
   
 
put-miR-471 AGAAGCAGAGAACGAGG -3.987795 8.44957 0.009973 0.119585 
put-miR-1352 TGGATTGTGGGGGAACC 5.478958 8.36409 0.010086 0.119857 
put-miR-610 AGGAGATATAGCTCTTGT 5.722079 8.518132 0.010392 0.122408 
put-miR-48 AAAATGGATTCGAACCA 5.632443 8.450136 0.010602 0.123785 
put-miR-529 TGACCTTTTGCCTTCTGC 5.426419 8.338572 0.010802 0.125018 
put-miR-424 TAAAAAGTTCTCTGTTTTTC -2.78953 7.208748 0.010937 0.12549 
put-miR-24 TTGGTGCATCTGTAGTCCAAC -4.932824 10.24045 0.011113 0.126418 
put-miR-164 TGAAATTCTAAATATTGCA 5.725561 8.51014 0.011372 0.126957 
put-miR-229 TGGGATTTAGCTCAGC 3.799609 8.12666 0.011424 0.126957 
put-miR-525 AAGTGGGAAGGCCCAGA -3.723862 8.317629 0.011446 0.126957 
put-miR-325 TTCAAATCCCACTTCTGACACCA -2.927094 7.781125 0.012443 0.136691 
put-miR-188 AAATGGCGATACTCAGG 6.335286 9.481014 0.012559 0.136691 
put-miR-1066 TGCTTTGATCGTAGCCC -3.205461 7.447675 0.012632 0.136691 
put-miR-1295 GAGGTTAGGATATCTGGCT -3.324069 7.580857 0.012893 0.13839 
put-miR-588 TTTTGAACGTTCTTTCTT 1.985563 8.910298 0.013328 0.141683 
put-miR-1273 AAGGGGAGGAATTTCACGTG 4.845324 8.579749 0.013413 0.141683 
put-miR-783 AAGGAAAAAGCGGATA -3.722555 7.559427 0.013621 0.14275 
put-miR-37 TGGTGGAGTGAAGACG -4.836261 8.547591 0.014174 0.14647 
put-miR-1317 TGGAGTGTGGATTGGGG 1.625507 8.870365 0.014196 0.14647 
put-miR-97 CTGCGTGGCTCTGACAC 3.27664 9.296956 0.014347 0.146889 
put-miR-1016 AGGTAAAGCTCATGAGG -2.141009 9.304303 0.014567 0.148003 
put-miR-546 CCAAGGGGTTGTAGGGCCACT 3.880018 10.64815 0.015027 0.15152 
put-miR-1099 AGACTCCTTTATCGTA 4.881265 8.359673 0.015178 0.151894 
put-miR-874 ATGAGCATTGATTTAGG -4.133563 8.481847 0.015742 0.15277 
put-miR-701 TTGAGATTTGAGGGGGCCT 2.361165 8.446935 0.015782 0.15277 
put-miR-279 CTGTGAAGCCTGTTGGTTTGCTGCTG -2.002787 8.036423 0.015783 0.15277 
put-miR-184 TGCTGAACCTCTGTATGT 5.624113 9.598097 0.015798 0.15277 
put-miR-495 CAGGGAGTGAAAGAGAATT -2.791411 9.973484 0.015923 0.15277 
put-miR-90 GAAGTTAAATCCTTGGG 3.643929 8.886684 0.016047 0.15277 
put-miR-468 ATAAGGAACTGCTCTCTC 4.936942 8.333361 0.016099 0.15277 
put-miR-469 GCGGGGGATTAGCTCAGCTGGG 1.223156 14.10575 0.016186 0.15277 
put-miR-1195 ATTCTTTGACATGCAGAT 2.561114 9.286221 0.016299 0.15277 
put-miR-250 CTGGTGTAGAATTGAGG -4.411037 8.166635 0.016733 0.153408 
put-miR-1264 CAGGTTTCAGACTTTAGG 2.452989 9.271027 0.0168 0.153408 
put-miR-465 CCAGTTGTCGTGGGTTTTT 2.030242 8.962972 0.016867 0.153408 
put-miR-1243 TGTGGATTTTTGTCATGT 4.743252 8.639084 0.016871 0.153408 
put-miR-771 CCTTGATCTGACTGGGGGCC -1.886812 8.602159 0.016943 0.153408 
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put-miR-534 CTGTTGGAGAATTTGGAATATTAGGT -4.34848 8.658536 0.01741 0.155563 
put-miR-80 GAAGAGGGAGTGGTCTGTAAATGCG 6.380693 9.533096 0.017415 0.155563 
put-miR-347 AAAGGGAAACAAGAATTCTT 1.937026 10.57284 0.017748 0.156927 
put-miR-410 GGAGAATAGAACATGCTGATT 6.652715 9.666187 0.017824 0.156927 
put-miR-891 TAAATGTTGGTTTGTTTGT 1.858836 8.369573 0.017921 0.156927 
put-miR-189 GAGCGAAACGGCAGGAT -2.368257 8.305643 0.018423 0.160266 
put-miR-842 ACCCGGAGAACTGAACT -2.045068 9.280359 0.01862 0.160514 
put-miR-81 ATTTGAAAGAATGCTTG 2.468711 8.296721 0.018693 0.160514 
put-miR-824 CTAGCTGAACCTCTGTAT 5.277761 8.805933 0.018935 0.161554 
put-miR-958 ACAGGGCTGTGCAAAAA 3.475245 8.121044 0.019332 0.163891 
put-miR-742 CAGGGCTGTGCTAACT 2.255055 7.794269 0.020414 0.171266 
put-miR-605 TGAGCTTTGGAAGAAGGACCA -2.303646 8.016644 0.020459 0.171266 
put-miR-374 TGTGAGGATGTTCTGTAAGGAGTGTT 4.607626 8.644756 0.020848 0.173428 
put-miR-135 TGAATTACGGAAGTGTTGGTTAAT -3.311813 7.404022 0.021756 0.179859 
put-miR-323 ATAAAATGGGCGTTGAGG 3.262325 8.71569 0.022489 0.184771 
put-miR-506 AAGAGGGGCTTTTAGAACC 6.174059 11.22955 0.022884 0.186859 
put-miR-293 GGGTAAAACTGCAGTGGGCGTTGGTAG -1.800636 10.99339 0.02336 0.189584 
put-miR-524 CGTGGTGATGCTCTGACA -2.434924 7.973262 0.023561 0.189632 
put-miR-517 TTGGGAAGGGCTGCCGGA -4.206993 8.774926 0.023651 0.189632 
put-miR-391 ATCTCGATCCAGTAGTC 1.801909 7.884667 0.024454 0.194897 
put-miR-92 AGAGACTGACTTTGAGTA 5.755643 9.030306 0.025075 0.198658 
put-miR-435 TTTAGACCGTTTTTATGTC -3.735696 9.202301 0.027033 0.212767 
put-miR-1080 TGTGGATTGATGCTCT -1.707634 8.549845 0.027175 0.212767 
put-miR-587 TTTGTAGAAGAGGAAGCG -2.497802 8.421284 0.029781 0.231807 
put-miR-1220 TAGAATGGGGCTTGTTGC 3.980805 8.446505 0.030296 0.233459 
put-miR-1134 AAAGAATGAAGTTGGTCTGG -1.684102 8.848135 0.030344 0.233459 
put-miR-352 TAATGAATGACTGTTTG 1.774841 8.080119 0.030753 0.23524 
put-miR-1162 AAAGAACGTTCAAAGG 2.807352 8.476403 0.030994 0.235731 
put-miR-377 AAAGGGCTTTGACTATTT 1.681479 13.05617 0.031488 0.237918 
put-miR-294 TGCTTCCTCAATCGGT 3.603279 8.466728 0.031639 0.237918 
put-miR-1229 ACAGTAGCAATGTTCTGC 3.278472 7.88184 0.032091 0.238095 
put-miR-1091 GATTATGATTGTGATTGTAGC 4.964642 9.493873 0.032144 0.238095 
put-miR-419 AAAAAGTTAGACTTAGG 1.437457 9.015693 0.032199 0.238095 
put-miR-249 GCCAGGATGTTGGCTTA -1.617688 9.173125 0.03244 0.238442 
put-miR-122 GGAACTCATGATTGTTGACTTTGG -1.814811 8.353927 0.032687 0.238442 
put-miR-1320 TTAGAGGCCACTCAAT 4.820365 8.331847 0.032994 0.238442 
put-miR-335 TATTTAAATGAGAACTTTGAAGC 2.147361 9.043008 0.033061 0.238442 
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put-miR-166 CGTTTTGGTGTTGGTTG -3.72297 8.052795 0.033142 0.238442 
put-miR-1172 AGAACCAAGAAGCTCTGG 2.612818 8.384166 0.034733 0.246677 
put-miR-1207 GTGAAAAGACATAGGGGG 1.882735 9.817827 0.034763 0.246677 
put-miR-1130 TAGAAGAGGGAGCTTCTTT 2.429349 9.717761 0.034842 0.246677 
put-miR-247 AGAGCTAGAATCCAGG 1.990242 8.786356 0.035469 0.249784 
put-miR-246 TTTATTAGAGACGGGACTTT 4.838701 8.30995 0.035789 0.250379 
put-miR-870 AAAGGATGTAGACAAGGGA 1.480442 8.130793 0.03593 0.250379 
put-miR-704 CAAATGAATATCTGGGA 2.582114 8.282107 0.037366 0.258799 
put-miR-266 TTTAGGTACTCTGAACAA 2.505244 8.581082 0.037586 0.258799 
put-miR-928 CACAGAAGGAACGTTTAGA 2.539814 8.530779 0.037862 0.258799 
put-miR-959 GAAAGAGAGTGAGACTCA 2.359451 8.451334 0.038062 0.258799 
put-miR-676 TGGTGGTTGGTTTTGGG -1.247728 9.504279 0.03818 0.258799 
put-miR-1095 ATTGTGAATGATCTGG 4.006586 8.691739 0.038403 0.258799 
put-miR-550 GCACTCTGGACTCTGAATCC -1.460704 9.782298 0.038501 0.258799 
put-miR-835 TTAGGAGTAGGTTACT 1.888177 8.674219 0.038693 0.258799 
put-miR-686 TGACTGTTTTATATGAGTAA 1.693385 10.42287 0.038917 0.258993 
put-miR-32 ATCCCGGACGAGCCCCCATTA -1.878608 11.03059 0.039456 0.260368 
put-miR-151 TTGAAACTGATATACTGTCTTAGG -2.781416 7.308382 0.039515 0.260368 
put-miR-726 GATGGGCTGATTGAGGGAT 3.117005 10.49059 0.039816 0.261058 
put-miR-256 ATGAGGCTGAGATTGTCC 1.962535 8.272489 0.040595 0.264863 
put-miR-368 AATGAGAACTTTGAAGGCCGAAG 2.363048 14.35762 0.041097 0.266314 
put-miR-1232 ACAGACTGTCTTTGGG 2.165428 8.620526 0.041263 0.266314 
put-miR-1219 GAAATTATTGATCCAGTCACGA 1.298803 9.720145 0.041418 0.266314 
put-miR-1276 GAAGAGTTGATCCATG -1.907277 9.309298 0.041682 0.266725 
put-miR-1119 GTTTTGGGTTGAGTGAGGA -2.455642 8.629875 0.042052 0.267807 
put-miR-901 GTCTATTTGGATTATCGTC 1.728483 8.113002 0.042255 0.267816 
put-miR-356 GTTTGAATTGGGAAGCTGGGGG -1.750022 8.007003 0.043232 0.272707 
put-miR-856 AAGGATAGGGAGGTATTT 2.182062 8.400665 0.044086 0.276787 
put-miR-1244 CAGTTGGTAGAGCACCTGAC -1.24774 10.46658 0.045019 0.281317 
put-miR-476 GTGGTCAGGTAGAGAA -1.919551 8.047207 0.046618 0.288241 
put-miR-142 CAGTATAATTAGGGGTTAATTGTGGGA 1.249016 8.70991 0.046684 0.288241 
put-miR-639 TGGAGTGTGGATTGGG 1.474835 8.945467 0.046777 0.288241 
put-miR-622 TGAGTGGTCAATGGGGG -1.336255 8.590784 0.047597 0.291931 
put-miR-337 TGGGCTCAAGCTTTCTCT -2.374139 8.27944 0.047999 0.291931 
put-miR-422 TTTAGGGTTTTAAGGTGTTA 1.290525 11.98963 0.048034 0.291931 
put-miR-1339 GGACTGAGAGCTCTTTCTG 3.091573 10.60449 0.048448 0.293113 
put-miR-1356 GTGCTGCATGGCTGTCA -1.345358 8.820822 0.049044 0.295237 
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put-miR-29 GAGATTTACGACCTAGG 1.337942 9.63023 0.049243 0.295237 
put-miR-128 TGGCTCTGACACTAGTA 2.165955 8.272955 0.049525 0.295593 
put-miR-359 GAAGTGGAAGGACTATGAA 2.152809 8.475685 0.050666 0.301056 
put-miR-1003 TGGACTTCAGAACAGC 4.029771 7.874318 0.050924 0.301242 
put-miR-238 AGAGACAGGAACTTTGATTTT 3.690637 8.383615 0.051316 0.302217 
put-miR-961 TAGCTTGATCCAGTTG 2.181109 9.760789 0.052445 0.307507 
put-miR-751 AGGCTGAGACTGGACAGAAAGACCT -1.317479 8.022761 0.053486 0.312239 
put-miR-1184 GCCTGCCCGGTGCTGGT 1.707305 8.999909 0.053825 0.312845 
put-miR-379 GCGTGTGCGCGGGAGG 2.352869 7.584474 0.054246 0.313921 
put-miR-361 CAGGTGAAATCGTGGATGT 2.224017 10.34793 0.05535 0.318896 
put-miR-1111 TGATGCGTTGGGATGTAGC -1.424105 8.543294 0.055717 0.318896 









eTable 2: List of 63 biomarkers validated in qPCR and used for statistical comparisons  
Panel A (23 microRNAs) 
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Panel C (11 putative microRNAs) 
small non coding 
RNAs Chr Strand Start Stop Sequence 
RNU4-6p X - 16893269 16893390 TATCGTAGCCAATGAGGTTTATCCGAGGCGTGATTATTGCTAATTGAAAA 
tRNA18ArgCCT 17 + 73030001 73030073 GCACTGGCCTCCTAAGCCAGGGATTGTGGGTTCGAGTCCCACCTGGGGTA 
U6.428 1 + 180727858 180727953 AAGATTAGCATGAGGATGACACGCAAATTCGTGAAGCGTTCCATTTCTTT 
RNU6-45 11 + 63737942 63738048 GGCCCTTGTGCAAGGATGACACGCAAATTCGTGAAGCGTTCCATATTTTT 
RNU6-4 1 - 31970419 31970525 GGCCCCTGCACAGGGATGACACGCAAATTCGTGAAGCGTTCCATATTTTT 
RNU6-6 2 + 201694732 201694839 GGCCCCTGTGCAAGGATGACACGCAAATTCGTGAAGCGTTCCATATTTTT 
RNU6-7 3 + 194935516 194935622 GGCCCCTGCGCAAGGATGACATGCAAATTCGTGAAGCGTTCCATATTTTT 
RNU6-73 13 + 28402900 28403006 GGCCCCTGTGCAAGGATGACATGCAAATTCGTGAAGCGTTCCATATTTTT 
SNORD3B 17 + 18965225 18965440 CTTCTCTCCGTATTGGGGAGTGAGAGGGAGAGAACGCGGTCTGAGTGGTT 
tRNA120-AlaAGC 6 - 28626014 28626085 GCGCATGCTTAGCATGCATGAGGTCCCGGGTTCGATCCCCAGCATCTCCA 
tRNA73-ArgCCG 6 + 28849165 28849237 GCGTCTGATTCCGGATCAGAAGATTGAGGGTTCGAGTCCCTTCGTGGTCG 
U6.168 6 - 18307204 18307310 ATGGCCCCTGCGCAAGGATGACACGCAAATTTGTGAAGGATTCCATATTT 
U6.375 4 + 109573306 109573412 GGCCCCTGTGCAAGAATGACTCGCAAATTCGTGAAGCGTTCCATATTTTT 
YRNA-684 18 + 20604559 20604666 GCTTCTTTTACTCTTTCCCTTCATTCTCACTACTGTACCTGATTCGTCTT 
U6.601 19 - 39287642 39287749 GGCCCCTGCGCAAGGATGACATGCAAATTTGTGAAGTGTTCCATATTTTT 
YRNA-255 17 + 80375102 80375197 GUGUCACCAACGUUGGUAUACAACCCCCCACAACUAAAUUUGACUGGCUU 
tRNA9-TyrGTA 7 + 149255133 149255205 CTTTTTGACTGTAGAGCAAGAGGTCCCTGGTTCAAATCCAGGTTCTCCCT 
U2.3 1 + 150209315 150209504 TCACTTCACGCATCGATCTGGTATTGCAGTACCTCCAGGAACAGTGCACC 
U4.64 9 + 36267780 36267919 GTATCGTAGCCAATGAGGTTTATCCAAGGTGCGATTATTGCTAATTGAAA 
SNORA57 10 + 27077946 27078086 TGCTGGCGGCTTCCCATCCGCTGGTTCTATCCTCAAACGCCGGGACACCG 
UC022CJG1 Y + 10037846 10037870 CATTGATCATCGACACTTCGAACGCACTTG 
tRNA27-MetCAT 6 + 26766444 26766516 GCGTCAGTCTCATAATCTGAAGGTCCTGAGTTCGAGCCTCAGAGAGGGCA 
tRNA8-ThrAGT 17 + 8090478 8090551 GCGCCTGTCTAGTAAACAGGAGATCCTGGGTTCGAATCCCAGCGGTGCCT 
tRNA2-LeuTAA 4 - 156384978 156385052 GCATAAAACTTAAAATTTTATAATCAGAGGTTCAACTCCTCTTCTTAACA 
YRNA-245 2 - 25919945 25920057 GTCTTTGTTGAACTCTTTCCCTCCTTCTCATTACTGTACTTGACCAGTCT 
snoU13.120 4 + 17530560 17530663 GCTACCCTGGAACCTTGTTATGACATCTGCACATTACCCATCTGACCTGA 
U6.1249 1 + 67661823 67661926 GATGGCATGACCCCTGATCAAGGACGGCATGCAAATTTGTGAAGTATTTC 
tRNA84-GluTCC 1 - 1.61E+08 1.61E+08 TTTCACCGCCGCGGCCCGGGTTCGATTCCCGGTCAGGGAA 
tRNA8-AlaTGC 12 + 1.25E+08 1.25E+08 TGCACGTATGAGGCCCCGGGTTCAATCCCCGGCATCTCCA 
Putative miRs Chr Strand Start Stop Sequence 
put-miR-1204 4 + 1661740 1661756 AGGGCTGGGCACGGGGG 
put-miR-1207 
X + 12647513 12647530 GTGAAAAGACATAGGGGG 
put-miR-465 
2 + 29475435 29475453 CCAGTTGTCGTGGGTTTTT 
put-miR-6 
16 + 67911172 67911188 GCGGACCTTGCTCAAGG 
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3 + 193330821 193330843 TTCAAATCCCACTTCTGACACCA 
put-miR-1146 5 + 67892184 67892199 ATAGGAGACTTCTATC 
put-miR-742 
16 + 49579869 49579884 CAGGGCTGTGCTAACT 
put-miR-476 
4 + 100244534 100244549 GTGGTCAGGTAGAGAA 






17 + 46822348 46822364 TGATTTTTTTTGGCGAA 
put-miR-1130 
2 + 1.13E+08 1.13E+08 TAGAAGAGGGAGCTTCTTT 
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eTable 3: Univariate analysis of comparisons at time point T1 
AUC, CI, count, ΔCq average, SD, ΔΔcq, fold change, t-test p value and power analysis for 
the comparison of individual biomarkers between HIA+ and HIA- in season 1. Samples were 




eTable 4: Univariate analysis of comparisons at time point T2 
AUC, CI, count, ΔCq average, SD, ΔΔcq, fold change, t-test p value and power analysis for each 
comparison of individual biomarkers between HIA+ and Uninjured, HIA- and MSK groups in season 
1. T-test  p values of season 2 are also reported when  found ≤ 0.05  







cq HIA- SD HIA+ SD HIA- 
cq  








(p = 0.05) 
hsa-miR-103a-3p 0.66 0.53-0.78 43/32 -20.11 -20.45 0.57 0.65 
0.34 1.27 
0.023 177 
hsa-miR-126-3p 0.71 0.58-0.84 37/28 -13.48 -14.56 1.19 1.89 
1.08 2.11 
0.012 108 
hsa-miR-144-3p 0.67 0.54-0.79 40/30 -14.46 -16.19 2.24 3.12 
1.73 3.32 
0.008 124 
hsa-miR-34b-3p 0.65 0.51-0.78 36/30 -13.93 -14.96 1.51 2.22 
1.03 2.04 
0.029 173 
hsa-miR-92a-3p 0.66 0.53-0.78 42/33 -20.57 -20.86 0.59 0.55 
0.29 1.22 
0.039 304 
HIA+ vs Uninjured 








 cq U 
SD 











(p = 0.05) 
t-test  
p-value  
 Season 2  
hsa-let-7f-5p 0.70 0.60-0.78 53/62 -16.24 -17.22 1.30 1.32 
      0.98 1.97 
0.000 96  
hsa-let-7a-5p 0.70 0.59-0.77 53/62 -20.09 -20.36 0.49 0.37 
0.27 1.21 
0.001 139 0.031 
hsa-let-7i-5p 0.65 0.55-0.73 53/62 -18.49 -18.72 0.42 0.49 
0.23 1.17 
0.010 234  
hsa-miR-135b-5p 0.68 0.58-0.76 50/61 -14.17 -14.80 0.90 0.97 
0.63 1.55 
0.001 122  
hsa-miR-34b-3p 0.75 0.66-0.83 34/45 -12.33 -13.99 2.02 2.46 
1.66 3.16 
0.002 104 0.046 
RNU6-4 0.67 0.57-0.76 53/61 -19.90 -21.00 2.19 1.78 
1.1 2.14 
0.004 181  
RNU6-45 0.66 0.56-0.75 53/62 -18.86 -19.90 2.19 2.20 
1.04 2.06 
0.013 250 0.016 
RNU6-6 0.65 0.56-0.74 53/61 -19.79 -20.73 2.00 1.79 
0.94 1.92 
0.009 228 0.051 
RNU6-7 0.64 0.55-0.73 53/62 -19.82 -20.74 2.01 1.78 
0.92 1.89 
0.010 236  
RNU6-73 0.65 0.55-0.73 53/62 -19.76 -20.65 1.87 1.80 
0.89 1.85 
0.011 238  
SNORD3B-2 0.65 0.55-0.74 53/62 -19.25 -19.83 1.62 1.24 
0.58 1.49 
0.033 321  
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YRNA-255 0.63 0.53-0.72 53/62 -22.71 -24.48 1.77 1.67 
1.77 3.41 
0.018 287  
hsa-miR-103a-3p 0.61 0.52-0.70 53/60 -19.70 -20.08 0.88 0.77 
0.38 1.30 
0.018 255  
U6.375 0.63 0.53-0.72 53/62 -16.38 -17.03 1.77 1.47 
0.65 1.57 
0.034 349  
U6.601 0.62 0.53-0.72 53/62 -18.17 -18.94 1.96 1.76 
0.77 1.71 
0.028 329  
YRNA-684 0.63 0.53-0.72 46/56 -12.30 -11.10 2.68 2.73 
-1.2 0.44 
0.028 254  
hsa-miR-107 0.59 0.49-0.68 53/62 -19.30 -19.61 0.93 0.73 
0.31 1.24 
0.047 150  










HIA+ SD HIA- 
cq  
  (HIA+) – 
(HIA-) 
Fold change 






(p = 0.05) 
t-test  
p-value  
 Season 2 
hsa-let-7a-5p 0.76 0.65-0.87 53/25 -20.09 -20.55 0.49 0.41 
0.46 1.38 
0.000 60  
hsa-let-7f-5p 0.89 0.82-0.96 53/25 -16.24 -17.90 1.29 0.56 
1.66 3.16 
0.000 26  
hsa-let-7i-5p 0.74 0.62-0.86 53/25 -18.49 -18.81 0.41 0.49 
0.32 1.25 
0.004 87  
hsa-miR-103a-3p 0.73 0.60-0.85 53/25 -19.70 -20.33 0.88 0.63 
0.63 1.55 
0.002 91 0.045 
hsa-miR-107 0.71 0.59-0.83 53/25 -19.30 -19.80 0.93 0.52 
0.5 1.41 
0.014 141  
has-miR-1246 0.63 0.50-0.76  53/25 -21.39 -2079 1.33 1.02 
-0.6 0.66 
0.031 200  
has-miR-135b-5p 0.81 0.71-0.91 50/25 -14.17 -15.08 0.90 0.51 
0.91 1.88 
0.000 44  
hsa-miR-144-3p  0.69 0.56-0.82 42/24 -14.19 -15.87 2.60 2.73 
1.68 3.20 
0.016 108  
hsa-miR-34b-3p 0.71 0.56-0.86  34/18 -12.33 -13.84 2.02 2.22 
1.51 2.85 
0.016 102  
hsa-miR-92a-3p 0.74 0.62-0.85 52/25 -20.38 -20.76 0.50 0.57 
0.38 1.30 
0.004 90  
put-miR-476  0.68 0.55-0.81 52/24 -16.19 -17.87 3.03 2.39 
1.68 3.20 
0.020 323  
put-miR-6 0.64 0.52-0.77 51/24 -14.42 -16.13 3.49 2.65 
1.71 3.27 
0.037 85 0.006 
RNU6-4 0.73 0.67-0.88  52/25 -19.90 -21.80 2.19 1.65 
1.9 3.73 
0.000 62  
RNU6-45 0.76 0.65-0.86 52/24 -18.86 -20.85 2.19 1.72 
1.99 3.97 
0.000 59 0.003 
RNU6-6 0.76 0.66-0.87  53/25 -19.78 -21.56 2.01 1.63 
1.78 3.43 
0.000 61 0.006 
RNU6-7 0.75 0.65-0.86  53/25 -19.82 -21.54 2.01 1.69 
1.72 3.29 
0.000 66 0.043 
RNU6-73 0.75 0.64-0.86 53/25 -19.76 -21.39 1.87 1.74 
1.63 3.10 
0.000 66 0.050 
SNORD3B-2 0.66 0.54-0.79 53/25 -19.25 -20.07 1.62 1.07 
0.82 1.77 
0.025 186 0.038 
tRNA120-AlaAGC 0.64 0.52-0.77 51/24 -16.29 -14.34 3.65 2.67 
-1.95 0.26 
0.023 98  
tRNA18-ArgCCT  0.72 0.61-0.84 53/25 -22.31 -23.74 1.80 1.67 
1.43 2.69 
0.001 73  
tRNA27-MetCAT 0.68 0.56-0.80 52/25 -18.36 -16.86 1.88 1.31 
-1.27 0.41 
0.030 176  
tRNA73-ArgCCG  0.68 0.56-0.80 52/25 -16.65 -18.12 2.31 1.72 
1.47 2.77 
0.006 66  
U2.3 0.64 0.51-0.76 53/25 -26.58 -27.64 2.13 0.96 
1.06 2.08 
0.003 162  
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eTable 5: Univariate analysis of comparisons at time point T3 
AUC, CI, count, ΔCq average, SD, ΔΔcq, fold change, t-test p value and power analysis for each 
comparison of individual biomarkers between HIA+ and Uninjured, HIA- and MSK groups in season 
1. T-test  p values of season 2 are also reported when  found ≤ 0.05. 
U6.375 0.71 0.59-0.83 53/25 -16.38 -17.70 1.77 1.58 
1.32 2.50 
0.002 92 0.005 
U6.601 0.72 0.61-0.84 53/25 -18.17 -19.73 1.96 1.75 
1.56 2.95 
0.001 77  
Y_RNA.255 0.70 0.58-0.81 53/25 -23.71 -24.94 1.77 1.40 
1.23 2.35 
0.003 93 0.038 









HIA+ SD MSK 










(p = 0.05) 
t-test  
p-value  
 Season 2 
tRNA18ArgCCT 0.73 
 



















































































































hsa-miR-144-3p 0.72 0.62-0.80 44/39 -12.54 -13.94 1.94 2.50 
1.4 2.64 
0.005 133  
hsa-let-7f-5p 0.63 0.52-0.72 55/46 -16.33 -16.95 1.44 1.41 
0.62 1.54 
0.033 279 0.007 
U6.1249 0.65 0.56-0.74 41/32 -10.16 -8.89 3.17 2.30 
-1.27 0.41 
0.051 221  
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hsa-let-7a-5p 0.69 0.52-0.82 55/20 -20.33 -20.62 0.56 0.43 
0.29 1.22 
0.042 154  
hsa-let-7f-5p 0.89 0.82-0.96 55/20 -16.33 -18.16 1.44 0.65 
1.83 3.56 
0.000 28 0.007 
hsa-miR-103a-3p 0.74 0.61-0.86 54/20 -19.71 -20.38 0.84 0.65 
0.67 1.59 
0.002 75 0.001 
hsa-miR-107 0.73 0.60-0.86 55/20 -19.31 -19.85 0.59 0.81 
0.54 1.45 
0.008 107 0.037 
hsa-miR-144-3p 0.69 0.55-0.83 44/20 -12.54 -14.01 1.94 2.44 
1.47 2.77 
0.012 161 0.000 
hsa-miR-148a-3p 0.66 0.51-0.80 55/20 -19.09 -19.62 1.11 0.55 
0.53 1.44 
0.007 212  
hsa-miR-21-5p 0.71 0.56-0.85 55/20 -21.88 -22.55 0.92 0.87 
0.67 1.59 
0.006 89 0.005 
hsa-miR-34b-3p 0.70 0.54-0.86 41/12 -12.34 -13.99 2.30 2.16 
1.65 3.14 
0.032 98 0.000 
put-miR-465 0.77 0.64-0.89 39/18 -13.15 -10.84 2.59 2.13 
-2.31 0.20 
0.002 1666  
RNU6-4 0.70 0.57-0.83 55/20 -20.26 -21.46 1.88 1.42 
1.2 2.30 
0.012 121  
RNU6-45 0.69 0.56-0.82 55/20 -19.22 -20.51 2.05 1.45 
1.29 2.45 
0.011 123  
RNU6-6 0.69 0.56-0.82 55/20 -20.09 -21.24 1.81 1.43 
1.15 2.22 
0.012 123 0.012 
RNU6-7 0.68 0.54-0.81 55/20 -20.13 -21.17 1.79 1.47 
1.04 2.06 
0.023 153 0.033 
RNU6-73 0.67 0.54-0.81 55/20 -20.02 -21.08 1.80 1.47 
1.06 2.08 
0.021 149  
tRNA2-LeuTAA 0.60 0.47-0.73 55/20 -17.03 -17.63 1.56 0.91 
0.6 1.52 
0.049 248  
U2.3 0.64 0.50-0.77 55/20 -26.57 -27.52 1.96 1.06 
0.95 1.93 
0.042 180  
U6.601 0.66 0.53-0.79 54/20 -18.42 -19.46 1.89 1.60 
1.04 2.06 
0.034 177  
snoU13.120 0.60 0.52-0.82 32/16 -12.59 -12.95 2.46 2.11 
0.36 1.28 
0.05 228 0.018 




































hsa-let-7f-5p 0.71  55/25 -20.33 -20.28 0.56 1.06 -0.05 0.97 0.011 107  
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eTable 6: Pairwise comparison of HIA+ and baseline values 
Count, ΔCq average, SD, ΔΔcq, fold change and paired-sample test for HIA+ values recorded in season 
1 at each time point and pre-season baseline.  
 
HIA+ (T1) vs 








(T1) SD B 
cq  
HIA+ (a) - B 
Fold change 





hsa-let-7f-5p 219 -18.01 -17.67 0.74 1.27 -0.35 -1.27 0.02 
























































0.49-0.78 55/25 -16.78 -17.60 1.57 1.92 0.82 1.77 0.046 
619 0.007 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Br J Sports Med
 doi: 10.1136/bjsports-2020-103274–10.:10 2021;Br J Sports Med, et al. Di Pietro V
   
 
   
 
put-miR-1207 207 -15.59 -12.28 3.27 2.22 -3.30 -9.88 0.00 
RNU4-6p 219 -17.44 -16.85 1.12 1.09 -0.59 -1.51 0.00 
put-miR-468 64 -14.10 -12.25 1.33 1.70 -1.85 -3.60 0.05 
has-miR-148a-3p 219 -19.97 -19.67 0.88 0.66 -0.29 -1.22 0.01 
hsa-miR-143-3p 114 -18.00 -18.17 0.99 0.92 0.16 1.12 0.00 
hsa-miR-34b-3p 182 -13.93 -12.33 1.51 1.87 -1.60 -3.04 0.00 
U2.3 219 -27.18 -27.13 1.32 1.31 -0.05 -1.03 0.01 
U4.64 107 -11.33 -11.90 2.36 2.64 0.57 1.49 0.00 
tRNA27-MetCAT 112 -18.60 -18.36 1.48 1.88 -0.24 -1.18 0.01 
hsa-let-7b-5p 219 -20.07 -20.26 0.58 0.58 0.19 1.14 0.00 
hsa-miR-142-3p 114 -23.48 -23.56 0.77 0.87 0.08 1.06 0.00 
hsa-miR-142-5p 219 -20.83 -20.14 0.90 1.03 -0.69 -1.61 0.00 
hsa-miR-29c-3p 219 -19.93 -19.74 0.58 0.58 -0.19 -1.14 0.00 
put-miR-1146 122 -12.59 -11.17 2.39 2.97 -1.43 -2.69 0.00 
tRNA2-LeuTAA 219 -16.87 -17.65 1.30 1.47 0.78 1.71 0.01 
tRNA9-TyrGTA 206 -13.04 -11.65 2.42 2.07 -1.39 -2.61 0.00 
YRNA-245 219 -15.50 -14.70 1.42 1.36 -0.80 -1.74 0.01 
HIA+ (T2)  vs B Count 
Average  
cq  





(T2)     SD B 
cq  
HIA+ (T2) - B 
Fold change 






hsa-let-7f-5p 229 -16.24 -17.67 1.30 1.27 1.43 2.69 0.01 
hsa-miR-1246 229 -21.39 -20.79 1.33 1.04 -0.60 -1.52 0.01 
hsa-miR-135b-5p 226 -14.17 -15.45 0.90 0.96 1.28 2.43 0.00 
hsa-miR-21-5p 229 -21.86 -22.45 0.99 0.74 0.59 1.51 0.03 
hsa-miR-425-5p 229 -18.87 -18.37 0.71 0.86 -0.50 -1.41 0.00 
put-miR-1207 217 -13.48 -12.28 3.36 2.22 -1.20 -2.30 0.04 
hsa-let-7a-5p 229 -20.09 -20.65 0.49 0.41 0.56 1.47 0.00 
hsa-miR-143-3p 229 -18.17 -17.60 0.92 1.18 -0.57 -1.48 0.00 
hsa-miR-34b-3p 180 -12.33 -12.33 2.02 1.87 0.00 -1.00 0.03 
SNORD3B 229 -19.25 -20.20 1.62 1.03 0.94 1.92 0.02 
U6.168 228 -16.74 -16.82 1.67 1.56 0.07 1.05 0.03 
YRNA-684 196 -12.30 -10.58 2.68 2.12 -1.72 -3.29 0.00 
hsa-miR-144-3p 208 -14.19 -13.70 2.60 2.06 -0.49 -1.41 0.01 
hsa-miR-16-1-3p 226 -14.16 -13.71 1.41 1.49 -0.45 -1.36 0.03 
put-miR-893 229 -28.04 -27.27 2.65 1.94 -0.77 -1.71 0.04 
U4.64 221 -11.90 -10.76 2.64 1.89 -1.14 -2.20 0.00 
SNORA57 229 -20.82 -20.63 1.15 1.06 -0.20 -1.15 0.04 
UC022CJG1 229 -22.04 -22.64 1.05 0.94 0.60 1.51 0.02 
hsa-let-7b-5p 229 -20.21 -20.26 0.90 0.58 0.05 1.04 0.01 
hsa-miR-142-3p 229 -23.56 -22.94 0.87 1.11 -0.63 -1.55 0.00 
hsa-miR-142-5p 229 -20.82 -20.14 0.97 1.03 -0.68 -1.61 0.00 
hsa-miR-29c-3p 229 -19.79 -19.74 0.90 0.58 -0.05 -1.04 0.01 
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tRNA2-LeuTAA 227 -16.87 -17.65 1.99 1.47 0.78 1.72 0.02 
tRNA9-TyrGTA 213 -13.06 -11.65 2.84 2.07 -1.41 -2.65 0.00 
YRNA-245 229 -15.18 -14.70 1.83 1.36 -0.48 -1.40 0.00 
hsa-miR-339-5p 229 -15.89 -15.50 1.60 1.30 -0.39 -1.31 0.02 
HIA+ (T3)  vs B Count 
Average  
cq  






(T3)    
 SD B 
cq  
HIA+ (T3) - B 
Fold change 






hsa-let-7f-5p 231 -16.33 -17.67 1.44 1.27 1.34 2.52 0.02 
hsa-miR-1246 231 -21.19 -20.79 1.21 1.04 -0.40 -1.32 0.01 
hsa-miR-135b-5p 228 -14.95 -15.45 0.96 0.96 0.50 1.41 0.00 
hsa-miR-21-5p 231 -21.88 -22.45 0.92 0.74 0.57 1.48 0.01 
U6.428 215 -13.10 -12.76 1.53 1.69 -0.34 -1.26 0.02 
U6.168 231 -16.78 -16.82 1.57 1.56 0.04 1.03 0.04 
YRNA-684 201 -11.24 -10.58 3.03 2.12 -0.66 -1.58 0.02 
hsa-miR-92a-3p 231 -20.47 -20.50 0.68 0.46 0.03 1.02 0.04 
U4.64 231 -16.98 -16.85 1.49 1.09 -0.13 -1.09 0.02 
U6.1249 160 -10.16 -8.96 3.17 2.18 -1.20 -2.30 0.02 
RNU4-6P 231 -16.98 -16.85 1.49 1.08 -0.13 -1.09 0.03 
 
eTable 7: Multivariable logistic regression analysis of concussion biomarkers across season-1 
(training dataset) and season-2 (test dataset) 
AUCs (95% CI) of biomarker panel in seasons 1 (training dataset) and season 2 (test dataset) across 
different comparisons and time points. Fourteen biomarkers were included in this model. Under all 
control groups, HIA-, uninjured and MSK controls are included. P values are shown underneath 
each comparison. 
 
HIA+ (CONCUSSED) vs. 
 All control groups HIA- Uninjured MSK controls Baselines 
      
SEASON 1 (2017-18) 
      
Time point T1 - 1  
(1-1) 
- - 1  
(1-1) 
p value  0.000   0.000 










p value 0.000 0.006 0.000 0.000 0.000 










p value 0.000 0.000 0.000 0.005 0.000 
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SEASON 2 (2018-19) 
      









p value 0.000 0.000 0.000 0.000  









p value 0.000  0.000 0.000 0.000  
 




has-miR-103a-3p Mean SD Min Median Max IQR CV 
 
  
Baseline -20.16 0.61 -22 -20.19 -17.47 0.69 -0.03   
                  
HIA+  T1 -20.11 0.58 -21.02 -20.18 -18.12 0.62 -0.03   
HIA+ T2 -19.7 0.88 -21.14 -19.81 -16.92 0.79 -0.04   
HIA+ T3 -19.71 0.84 -20.76 -19.92 -16.4 0.85 -0.04   
                  
HIA- T1 -20.45 0.65 -22.27 -20.38 -18.87 0.62 -0.03   
HIA- T2 -20.33 0.63 -22.01 -20.28 -18.73 0.66 -0.03   
HIA- T3 -20.38 0.65 -22.21 -20.31 -18.98 0.39 -0.03   
                  
has-let-7a-5p Mean SD Min Median Max IQR CV 
 
  
Baseline -20.56 0.41 -22.09 -20.66 -19.59 0.48 -0.02   
                  
HIA+  T1 -20.46 0.51 -21.69 -20.38 -19.15 0.56 -0.02   
HIA+ T2 -20.09 0.49 -20.95 -20.06 -28.86 0.57 -0.02   
HIA+ T3 -20.33 0.56 -22.33 -20.32 -19.08 0.65 -0.03   
                  
HIA- T1 -20.61 0.44 -21.55 -20.55 -19.89 0.57 -0.02   
HIA- T2 -20.55 0.41 -21.56 -20.51 -19.55 0.44 -0.02   
HIA- T3 -20.62 0.43 -21.51 -20.65 -19.53 0.37 -0.02   
                  
Uninjured T2 -20.36 0.37 -21.18 -20.35 -19.65 0.47 -0.02   
Uninjured T3 -20.49 0.61 -21.63 -20.52 -18.14 0.75 -0.03   
                  
MSK  T2 -20.26 0.72 -21.23 -20.52 -18.29 0.65 -0.04   
MSK  T3 -20.38 0.62 -21.22 -20.22 -18.74 0.85 -0.03   
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Uninjured T2 -20.08 0.77 -21.88 -20.17 -17.85 0.91 -0.04   
Uninjured T3 -19.87 0.88 -21.15 -19.99 -17.27 0.71 -0.04   
                  
MSK  T2 -19.82 0.79 -21.45 -19.83 -17.52 0.78 -0.04   




has-miR-143-3p Mean SD Min Median Max IQR CV 
 
  
Baseline -17.6 1.81 -20.95 -17.77 -13.9 1.62 -0.07   
                  
HIA+  T1 -18.03 0.85 -19.43 -18.1 -15.7 1.25 -0.05   
HIA+ T2 -18.17 0.92 -19.58 -18.36 -15.74 1.27 -0.05   
HIA+ T3 -17.56 1.08 -19.4 -17.78 -15.25 1.32 -0.06   
                  
HIA- T1 -18.14 0.79 -19.78 -18.23 -16.36 1.19 -0.04   
HIA- T2 -17.93 0.82 -19.52 -17.91 -16.67 1.23 -0.05   
HIA- T3 -17.91 1.02 -19.7 -17.99 -15.74 1.28 -0.06   
                  
Uninjured T2 -18 0.99 -19.91 -18.01 -16.03 1.29 -0.05   
Uninjured T3 -17.68 1.01 -19.5 -17.48 -16.06 1.63 -0.06   
                  
MSK  T2 -17.46 1.03 -19.7 -17.57 -16.18 1.24 -0.06   
MSK  T3 -17.01 1.25 -19.59 -17.32 -14.59 1.75 -0.07   
          
has-miR-34b-3p Mean SD Min Median Max IQR CV 
 
  
Baseline -12.33 1.87 -17.73 -12.04 -8.45 2.44 -0.15   
                  
HIA+  T1 -13.93 1.51 -17.12 -14.06 -10.29 2.3 -0.11   
HIA+ T2 -12.33 2.02 -16.98 -12.18 -8.71 2.47 -0.16   
HIA+ T3 -12.34 2.3 -16.82 -11.69 -7.47 3.4 -0.19   
                  
HIA- T1 -14.96 2.22 -20.24 -14.85 -10.44 2.37 -0.15   
HIA- T2 -13.84 2.22 -18.91 -13.63 -9.58 1.76 -0.16   
HIA- T3 -13.99 2.16 -17.67 -13.71 -10.4 1.89 -0.15   
                  
Uninjured T2 -13.97 2.48 -19.2 -13.85 -9.21 3.41 -0.18   
Uninjured T3 -13.04 2.14 -19.39 -13.04 -8.9 2.81 -0.16   
                  
MSK  T2 -12.84 1.58 -15.19 -12.66 -9.71 2.65 -0.12   




RNU6.45 Mean SD Min Median Max IQR CV   
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Baseline -19.96 1.72 -23.6 -20.1 -14.29 2.29 -0.09   
                  
HIA+  T1 -20.04 1.91 -23.82 -19.88 -14.64 2.15 -0.1   
HIA+ T2 -18.86 2.19 -24.09 -18.92 -11.97 2.82 -0.12   
HIA+ T3 -19.22 2.05 -23.87 -19.05 -14.69 1.85 -0.11   
                  
HIA- T1 -20.18 1.74 -23.27 -19.94 -16.78 2.55 -0.09   
HIA- T2 -20.81 1.73 -23.7 -20.06 -18.29 2.33 -0.08   
HIA- T3 -20.51 1.45 -22.87 -20.72 -18.38 2.33 -0.07   
                  
Uninjured T2 -19.86 2.2 -23.61 -20 -13.53 2.95 -0.11   
Uninjured T3 -19.65 2.39 -23.74 -19.92 -13 2.94 -0.12   
                  
MSK  T2 -20.32 2.21 -24.03 -20.64 -14.45 2.88 -0.11   
MSK  T3 -20.14 2.45 -23.49 -20.32 -12.75 2.86 -0.12   
 
 
RNU6.7 Mean SD Min Median Max IQR CV 
 
  
Baseline -20.6 1.67 -24.25 -20.76 -15.07 2.22 -0.08   
                  
HIA+  T1 -20.81 1.67 -24.4 -20.4 -17.9 2.06 -0.08   
HIA+ T2 -19.82 2.01 -24.56 -19.83 -13.14 2.2 -0.1   
HIA+ T3 -20.13 1.79 -24.49 -19.72 -16.32 1.69 -0.09   
                  
HIA- T1 -20.9 1.59 -23.89 -20.46 -17.33 2.22 -0.08   
HIA- T2 -21.54 1.69 -24.42 -20.77 -19.18 2.72 -0.08   
HIA- T3 -21.17 1.47 -23.75 -21.4 -18.89 2.34 -0.07   
                  
Uninjured T2 -20.72 1.78 -24.54 -20.76 -16.84 2.5 -0.09   
Uninjured T3 -20.45 2.01 -24.23 -20.63 -14.71 2.56 -0.1   
                  
MSK  T2 -21.11 1.77 -24.29 -21.11 -17.3 2.35 -0.08   
MSK  T3 -20.96 2.11 -23.94 -21.27 -16.21 3.14 -0.1    
 
 
snoU13.120 Mean SD Min Median Max IQR CV    
Baseline -12.48 2.46 -25.84 -11.96 -8.22 2.87 -0.2    
                   
HIA+  T1 -13.81 3.06 -19.83 -14.5 -8.4 5.06 -0.22    
HIA+ T2 -13.81 3.08 -21.42 -13.53 -7.96 4.33 -0.22    
HIA+ T3 -12.59 2.47 -18.12 -12.05 -8.49 3.76 -0.2    
                   
HIA- T1 -12.07 2.31 -16.76 -11.71 -9.39 2.91 -0.19    
HIA- T2 -12.87 2.17 -16.62 -13.06 -6.96 1.67 -0.17    
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HIA- T3 -12.95 2.11 -19.62 -12.63 -10.29 1.98 -0.16    
                   
Uninjured T2 -12.91 2.68 -18.88 -12.71 -4.96 3.04 -0.21    
Uninjured T3 -13.13 2.57 -18.48 -12.52 -9.09 3.93 -0.2    
                   
MSK  T2 -14.19 2.69 -20.59 -14.44 -9.39 3.41 -0.19    
MSK  T3 -13.18 2.32 -17.03 -13.57 -9.29 3.5 -0.18    
 
tRNA18.ArgCCT Mean SD Min Median Max IQR CV 
 
  
Baseline -22.9 1.62 -26.92 -23 -18.51 2.11 -0.07   
                  
HIA+  T1 -22.56 1.67 -26.42 -22.15 -19.59 2.02 -0.07   
HIA+ T2 -22.31 1.8 -27.33 -22.1 -19.26 2.31 -0.08   
HIA+ T3 -22.59 2.16 -26.36 -22.31 -18.11 3.5 -0.1   
                  
HIA- T1 -22.77 1.53 -25.76 -22.59 -19.4 1.86 -0.07   
HIA- T2 -23.77 1.67 -26.61 -23.61 -21.31 2.86 -0.07   
HIA- T3 -23.08 1.28 -25.24 -23.08 -20.22 1.35 -0.06   
                  
Uninjured T2 -22.8 1.66 -26.3 -22.84 -18.87 2.31 -0.07   
Uninjured T3 -22.6 1.59 -26.05 -22.8 -18.72 2.23 -0.07   
                  
MSK  T2 -23.57 1.45 -26.6 -23.45 -21.27 1.62 -0.06   
MSK  T3 -23.74 1.6 -26.49 -23.87 -21.02 2.52 -0.07   
          
 
U6.1249 Mean SD Min Median Max IQR CV 
 
  
Baseline -8.96 2.18 -14.88 -8.64 -4.36 2.8 -0.24   
                  
HIA+  T1 -9.89 2.48 -16.57 -9.42 -4.99 2.99 -0.25   
HIA+ T2 -9.68 2.9 -17.46 -8.78 -5.31 4.57 -0.3   
HIA+ T3 -10.16 3.17 -17.81 -9.81 -5.57 5.42 -0.31   
                  
HIA- T1 -10.27 2.56 -15.78 -10.14 -5.48 2.61 -0.25   
HIA- T2 -9.83 1.67 -12.61 -9.77 -7.11 2.2 -0.17   
HIA- T3 -9.99 2.73 -17.29 -9.09 -6.39 1.72 -0.27   
                  
Uninjured T2 -9.92 2.65 -15.08 -9.75 -5.32 3.51 -0.27   
Uninjured T3 -8.89 2.3 -16.74 -8.7 -4.66 2.36 -0.26   
                  
MSK  T2 -9.94 2.36 -14.58 -9.81 -5.74 3.57 -0.24   
MSK  T3 -10.51 1.89 -13.23 -10.36 -7.27 2.38 -0.18   
 
U6.168 Mean SD Min Median Max IQR CV 
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Baseline -16.82 1.56 -20.2 -16.76 -11.76 1.96 -0.09   
                  
HIA+  T1 -17.07 1.38 -20.17 -16.69 -15.07 1.94 -0.08   
HIA+ T2 -16.74 1.67 -21.16 -16.53 -12.15 2.39 -0.1   
HIA+ T3 -16.78 1.57 -20.3 -16.41 -14.48 2.47 -0.09   
                  
HIA- T1 -17.01 1.46 -19.91 -17.03 -13.77 2.24 -0.09   
HIA- T2 -17.46 1.49 -20.04 -17.06 -15.32 2.06 -0.09   
HIA- T3 -17.37 1.43 -19.74 -17.02 -15.37 2.12 -0.08   
                  
Uninjured T2 -17.16 1.55 -20.01 -17.13 -13.29 2.08 -0.09   
Uninjured T3 -17.04 1.64 -20.15 -16.98 -13.97 2.41 -0.1   
                  
MSK  T2 -17.78 1.62 -20.69 -17.89 13.73 2.48 -0.09   
MSK  T3 -17.6 1.92 -20.67 -17.64 -13.8 2.96 -0.11   
          
 
 
U6.428 Mean SD Min Median Max IQR CV 
 
  
Baseline -12.76 1.69 -16.74 -12.74 -7.8 1.92 -0.13   
                  
HIA+  T1 -12.69 1.51 -16.27 -12.45 -10.55 2.02 -0.12   
HIA+ T2 -12.87 1.62 -16.69 -12.87 -9.62 1.88 -0.13   
HIA+ T3 -13.1 1.53 -16.65 -12.82 -9.7 1.86 -0.12   
                  
HIA- T1 -12.9 1.49 -15.61 -12.8 -10.43 2.4 -0.12   
HIA- T2 -13.27 1.8 -16.31 -13.14 -10.05 2.71 -0.14   
HIA- T3 -13.05 1.49 -16.29 -12.72 -10.84 2.29 -0.11   
                  
Uninjured T2 -13.33 1.56 -16.43 -13.42 -9.05 1.73 -0.12   
Uninjured T3 -13.27 1.39 -15.72 -13.09 -10.78 2.31 -0.11   
                  
MSK  T2 -13.6 1.69 -17.3 -13.89 -10.43 2.16 -0.12   
MSK  T3 -14.26 1.59 -17.55 -13.93 -11.46 2.41 -0.11   
 
 
uc022cjg1 Mean SD Min Median Max IQR CV 
 
  
Baseline -22.64 0.94 -25.76 -22.62 -20.14 1.12 -0.04   
                  
HIA+  T1 -22.36 0.89 -24.48 -19.54 -20.72 0.94 -0.04   
HIA+ T2 -22.04 1.05 -24.32 -22.12 -19.54 1.21 -0.05   
HIA+ T3 -22.57 1.16 -25.04 -22.69 -19.63 1.43 -0.05   
                  
HIA- T1 -22.18 0.82 -23.64 -22.15 -20.47 1.03 -0.04   
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HIA- T2 -22.36 1.17 -25.66 -22.45 -19.44 1 -0.05   
HIA- T3 -22.82 0.9 -25.3 -22.68 -21.58 0.74 -0.04   
                  
Uninjured T2 -22.28 1 -24.09 -22.38 -19.96 1.35 -0.04   
Uninjured T3 -22.32 1.03 -24.59 -22.22 -19.25 1.03 -0.05   
                  
MSK  T2 -22.65 0.99 -25.68 -22.77 -21.01 1.05 -0.04   




Y-RNA.255 Mean SD Min Median Max IQR CV 
 
  
Baseline -24.11 1.65 -27.32 -24.21 -19.59 2.42 -0.07   
                  
HIA+  T1 -24.28 1.6 -27.77 -23.99 -20.99 1.96 -0.07   
HIA+ T2 -23.71 1.77 -27.23 -23.88 -19.37 2.59 -0.07   
HIA+ T3 -23.91 1.76 -27.77 -23.53 -20.53 2.81 -0.07   
                  
HIA- T1 -24.411 1.43 -26.97 -24.23 -21.67 2.43 -0.061   
HIA- T2 -24.94 1.4 -27.74 -24.6 -22.62 2.25 -0.06   
HIA- T3 -24.45 1.29 -26.59 -24.41 -21.87 1.9 -0.05   
                  
Uninjured T2 -24.44 1.65 -28.621 -24.65 -20.7 2.47 -0.071   
Uninjured T3 -23.99 1.97 -27.59 -24.25 -17.77 2.54 -0.08   
                  
MSK  T2 -24.77 1.67 -27.38 -24.86 -19.95 2.1 -0.07   




After independent review of the incidents, 47 cases were excluded due to incomplete HIA 
documentation or failure to identify a clear mechanism of injury on the video footage. The 
analysis of the complete dataset including the excluded incidents does not show substantial 
differences from the censored data. The full uncensored dataset analysis is reported in the 
eTable 9. The overlap with the previous analysis is evidenced in grey cells. 
 
eTable9: Analysis of uncensored data. Cells in grey match the biomarkers of eTable 3,4 
and 5 
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eTable 10. Classifications of MSK Injuries by body part and injury type 
Injury details were available for samples from 22 players. The remainder either did not have 
information available (players from the Championship competition) or had an injury resulting 
in less than 24 hours lost from full participation. 
 
n=22 Number (%) 
  
Body Part  
Shoulder 2 (9.10) 
Forearm/Hand 4 (18.18) 
Thoracic Spine 1 (4.55) 
Abdomen/Trunk 2 (9.10) 
Hip 1 (4.55) 
Knee 1 (4.55) 
Lower Leg 3 (13.64) 
Foot/Ankle 8 (36.36) 
  
Injury Type  
Ligament Sprain 11 (50) 
Haematoma/Contusion 4 (18.18) 
Fracture 3 (13.64) 
Muscle Strain 1 (4.55) 
Dislocation 1 (4.55) 
Other 2 (9.10) 
 
eFigure 1: Heat map of KEGG pathway analysis of  differentially expressed microRNAs  
found in the comparison HA+ vs HIA- at T1.  
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eFigure 2: Heat map of KEGG pathway analysis of  differentially expressed microRNAs  
found in the comparison HA+ vs HIA-  at T2. 
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eFigure 3: Heat map of KEGG pathway analysis of  differentially expressed microRNAs  
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